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Abbreviations:  
 
aHR = adjusted hazard ratio 
AV = arteriovenous (fistula or graft) 
ABPM = ambulatory blood pressure monitoring 
AKI = acute kidney injury 
AKIN = acute kidney injury network 
ANCOVA = analysis of covariance  
AN-69 = a type of polyacrylonitrile dialysis membranes 
Apache II = "Acute Physiology and Chronic Health Evaluation II": a severity-of-disease 
scoring system specific for Intensive Care Units 
aPTT = activated partial thromboplastin time 
ARF = acute renal failure 
BIA = bioimpedance analysis (a.k.a. Bioimpedance Spectroscopy, BIS; or Body 
Composition Monitoring, BCM) 
BMI = body mass index 
BNP = brain-type natriuretic peptide 
BP = blood pressure 
BSA = body surface area 
BUN = blood nitrogen 
CBC = complete blood count 
CHF = congestive heart failure  
CKD = chronic kidney disease 
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CKD-EPI = Chronic Kidney Disease Epidemiology (formula to calculate estimated 
glomerular filtration rate) 
CRP = C-reactive protein 
CRRT = continuous renal replacement therapy 
CV = cardiovascular 
DOPPS = Dialysis Outcomes Practice Pattern Study  
ED = Emergency Department 
EDW = estimated dry weight 
ESRD = end-stage renal disease 
GI = gastrointestinal  
GFR = glomerular filtration rate 
HD = hemodialysis 
HIV = human immunodeficiency-virus 
ICU = Intensive Care Unit 
IDWG = interdialytic weight gain 
INR = international normalized ratio (of prothrombin time) 
IV = intravenous 
IQR = 25-75% interquartile range 
KDIGO = Kidney Disease Improving Global Outcomes 
KDQOI = Kidney Disease Outcomes Quality Initiative 
Kt/V = single-pool urea clearance; dimensionless expression of dialysis adequacy 
NKF = National Kidney Foundation (of the United States) 
OR = Odds Ratio  
PT = prothrombin time 
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RIFLE = risk/injury/failure/loss/end-stage (classification stages of Acute Kidney Injury) 
RRF = residual renal function 
RRT = renal replacement therapy 
TDC = tunneled dialysis catheter 
PD = peritoneal dialysis 
UF = ultrafiltration 
UFR = ultrafiltration rate 
UMMC = University of Mississippi Medical Center  
US = United States (of America) 
VRWG = volume-related weight gain 
WBC = white blood cell count 
95% CI = 95% confidence intervals 
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1. Introduction 
1.1. Preamble: the burden of end-stage renal disease world-wide 
Survival for end-stage renal disease (ESRD) patients remains dismal and much 
below of their age-adjusted peers. We are far from being able to deliver true cure for 
chronic renal failure and our technology to replace the functions of the native kidneys is 
imperfect at best. During the care of these patients many issues remain insufficiently 
addressed and likely to contribute to adverse outcomes. At a time of increasing burden of 
chronic kidney disease (CKD) in the aging population and escalating load of prevalent 
ESRD patients, our specialty is under siege by shrinking reimbursement in the 
industrialized part of the world, inadequate resources and limitations of trained manpower 
in most places of the globe. Clinical nephrology training is demanding, requiring 
excellent cognitive skills and years of dedicated training to deliver optimal care; a 
competent nephrologist is much more than a “dialysis doctor”. Yet, at the same time, 
interest in nephrology has reached an all-time low, a phenomenon observed world-wide 
(1, 2). Under such circumstances, we should judiciously re-assess the available resources, 
both societal and of the health care practitioners’, to ensure the best possible care for our 
patients. Further, we should scrutinize existing knowledge and stimulate interest among 
trainees, both in research and clinical care, to maintain attraction for the specialty and 
seek new solutions for our ever-changing clinical problems. There is yet much to be 
learned about the care of these patients; call for action for all of us. 
 
1.2 Importance of time during renal replacement therapy   
Relying predominantly on small solute clearance (3), including single-pool urea 
clearance (Kt/V) and creatinine removal to define adequacy of renal dialysis constitutes 
perhaps the “original sin” of clinical nephrology. Historically, an adequate Kt/V was 
mediated by the combination of filter clearance and time spent on renal replacement 
therapy. With evolving technology, using larger surface area filters and higher flow rates, 
identical Kt/Vs have been re-created but within a much shorter time, leading to a potential 
deterioration of overall well-being and hemodynamical stability. In the largest dialysis 
trial to date, participants assigned to higher Kt/V with high-flux dialysis were more likely 
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to experience hypotension (4). Progressive decline of hemodialysis (HD) time was indeed 
the rule in the U.S. for most of the late 90s and the early 2000s; many limitations of 
reduced time with such approach were not sufficiently appreciated until the current 
decade. Among these are that Kt/Vs are not normalized for the body surface area (BSA), 
may impact smaller subjects differently (including women) (5) and do not account for 
differences in body compositions (6). It is virtually impossible to deliver identical 
clearance characteristics during an inherently discontinuous therapy (4 hours, three times 
a week) to replace the smooth 24-hour function of the native kidneys. The clearance of 
large-size uremic toxins will be primarily a matter of time spent on renal replacement 
therapy (RRT) (7-10). Several markers of uremia (phenylacetylglutamine, hippurate, 
indoxyl sulfate) maintain a markedly elevated level on chronic hemodialysis (x40-120) 
despite receiving what appears to be an adequate RRT (11, 12). During the care ESRD 
patients, the last 2 decades have witnessed an evolving shift from purely biochemical 
determinants of outcome (e.g. urea clearance, hemoglobin, phosphate and parathyroid 
hormone control) to a broader view emphasizing the use of fistulas, pre-dialysis 
nephrology care, and maneuvers to preserve residual renal function (13). Additional 
considerations are the length of effective dialysis received, the presence of inflammation 
with vascular access catheters and suboptimal compliance with dietary and fluid 
restrictions (14). As volume removal and ultrafiltration rates are almost impossible to 
disengage from dialysis duration in chronic outpatient dialysis, excess fluid gains and/or 
insufficient time on dialysis will result volume overload and worsening blood pressure 
(BP) control. Since the publication of our original publication on the importance of time 
during renal hemodialysis (13), significant advancement and new knowledge has 
accumulated on the subject and will be discussed in this current thesis.    
 
1.3 Blood pressure control in hemodialysis patients 
The current approach of excessive reliance on BP measurement at and around the 
time of the dialysis procedure to assess overall BP control is difficult to support (15). BP 
monitoring during HD is done primarily to ensure the safety of renal dialysis. Extreme 
caution should be exercised to extrapolate HD-associated BP to judge the efficacy of BP 
control in the outpatient setting (16). Optimal BP targets in dialysis patients are subjects 
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to debate (16) and the link between hypertension and poor cardiovascular outcomes is 
less clear than in the case of the general population. The assessment of BP for these 
patients comprises multiple limitations: the functioning arterio-venous (AV) grafts and 
fistulas in the upper extremities, the presence of peripheral vascular disease (17-19), 
inappropriately small BP cuffs in the obese (20) and misleadingly high BP immediately 
after clinic arrival pressure (21). Abrupt changes in fluid volume and plasma ion 
concentration during HD treatment will frequently predispose patients to erratic BP 
changes. In the largest controlled trial to date, those assigned to higher Kt/V were more 
likely to have hypotensive episodes (equilibrated Kt/V of 1.45 vs 1.05, 18.3% versus 
16.8%; p<0.001) (4). On the other hand, BP stability at and around the time of 
hemodialysis confers a lower risk of mortality independent of the actual BP values and 
persisting through a 2-year follow-up period (22). Climatic circumstances may influence 
blood pressure but so may the interdialytic weight gain (IDWG): e.g., in one study, cooler 
temperatures were associated with higher systolic blood pressure, IDWG, and serum 
potassium values across the United States (23). Similarly, in a cohort of 100 ESRD 
subjects we also observed some influence of “hot and dry” environmental temperatures 
on IDWG (24).  
Ambulatory blood pressure monitoring (ABPM) circumvents many problems of 
unit-derived BP measurements. It relieves the provider from the burden of making BP 
management decisions based on HD unit-based measurements, known to be highly 
inaccurate and heterogeneous across the population (25). It poses minimal inconvenience 
to the patients (26) and has better long-term reproducibility than casual blood pressure 
measurement in hemodialysis patients (27, 28). Abbreviated ABPM monitoring or a 
limited number of BP readings in the outpatient setting convey prognostic information 
similar to more extensive monitoring (29). Home BP self-recording assesses out-of-unit 
BP burden well (28), is easy to repeat and represents a simple and low-cost alternative to 
ABPM (16). Similarly to past studies, we also have demonstrated that the post-dialytic 
BP had a better association with 48-hour BP burden during ABPM than the predialysis 
BP (30). A recent paper by Agarwal et al. has explored the clinical utility of intra-dialytic 
BP recording in estimating the out-of-the-dialysis-unit BP load (31), conferring to the 
usual clinical practice of nephrologists to review intra-dialytic BP fluctuations when 
establishing the patients’ ideal target weights.  Significant practice variation exists across 
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countries with regard to the nephrologists being present during dialysis, conceivably 
compromising the practicability of this approach in many places (32). 
 
1.4 Dry weight determination in hemodialysis patients 
Defining the ideal volume status and weight continues to be a challenge in clinical 
practice dialysis (33-35).  Elevated BP may or may not equate with hypervolemia. In 
brief, one needs to find a target or “ideal” weight where both symptomatic fluid overload 
before dialysis and hypotensive episodes during and after treatments are minimized to as 
little as possible. There have been many attempts to define such an optimal volume status 
via scientific, objective and reproducible means (36). The historical practice pattern (37) 
has been to “challenge” the patients’ target weight by gradual  escalation of ultrafiltration 
goals during renal dialysis and, as needed, re-administer IV fluids for hypotensive events 
and/or symptomatic hypovolemia. As crude as this practice pattern appears, little has 
changed in clinical practice over the last three decades and the concept of “physician-
estimated dry weight” or “physician-declared dry weight” remained well-entrenched in 
textbooks. These maneuvers, however, can be very distressing to patients and create extra 
labor and alarm for the dialysis unit care staff (38). Dry weight, probed to a symptomatic 
threshold (37) causes not only hypotension but also sympathetic activation, potentially 
triggering  acute cardiovascular and vascular access events (39). Repetitive end-dialytic 
weight below estimated dry weight (EDW) is associated with worsened survival (40). 
Additional concerns for such an approach are ischemia in the mesenteric (41) or 
peripheral vascular supply territories (42), both of which could carry a high mortality rate. 
Further complicating care is the fact that in certain countries (e.g. U.S.), shortage of 
physicians and the reimbursement paradigm do not provide an incentive for clinicians to 
be present during RRT and assess intra-dialytic BP changes during the sessions (32). 
Hence, variation of ultrafiltration goals will be determined by mid-level providers or 
worse, the dialysis nurse on site. Physicians may have limited time, if some, to review 
care charts of RRT sessions. 
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1.5 The interaction between volume status and blood pressure: limitations of 
physical examination to assess volume status  
Establishing the optimal volume status is exceedingly difficult in the multiple co-
morbid ESRD cohort. The physical examination may have severe limitations in assessing 
the necessary or, more importantly, the possible tolerated amount of ultrafiltration (43). 
Similarly to time on hemodialysis, volume management has not received sufficient 
attention by decision-maker parties of ESRD-care until very recently (44). Fluid overload 
is associated with a graded elevation of blood pressure before dialysis (45) and excessive 
interdialytic fluid gains are associated with worsened survival (46, 47). Clearly, escalating 
anti-hypertensive therapy alone is insufficient (48-50) without addressing the 
extracellular fluid space expansion (6, 51, 52), the root cause of hypertension among these 
subjects. On the other hand, aggressive volume control may accelerate the development 
of full anuria (53), further compromising downstream management for these patients. At 
both two extremes, in volume depletion-related hypotension and hypotension induced by 
excessive ultrafiltration with large IDWGs, physicians may respond by increasing the 
estimated dry weight; however, in the latter case this would only escalate the volume-
overloaded state further (54). Accordingly, it is critical to be able to determine the relative 
contribution of volume overload to elevated blood pressure in a reproducible, observer 
independent, standardized manner. The judicious challenge of the target weight remains 
an important element of blood pressure management in daily practice of nephrology at 
present time (52, 55). Clearly, a subset of patients have volume-independent hypertension 
(56) and these subjects need to be identified, as well.  Available tools include imaging 
procedures (chest ultrasonography, inferior vena cava diameter assessment, 
echocardiography), biomarkers such as atrial and B-natriuretic peptides (38) and, more 
recently, bioimpedance analysis (BIA) (6, 38, 57, 58) and blood volume monitoring (59, 
60).  
 
1.6 Inflammation and C-reactive protein 
C-reactive protein (CRP) is an acute phase protein, clinically attractive as an in 
vivo bioassay to gauge the overall degree of inflammation (61).  Elevated CRP has also 
emerged as a non-traditional risk factor for adverse cardiovascular outcomes in the 
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general population, potentially adding to conventional vascular risk assessment for non-
renal patients (62, 63). The relationship between CRP and hypertension is directional:  
hypertension is not only associated with elevated CRP in non-renal patients (64), but 
among normotensive subjects, elevated CRP increases the future risk of hypertension 
(65). Elevated CRP levels are associated with cardiovascular (CV) disease and mortality 
(66-68), sudden cardiac death (67) and stroke (69), possibly mediated through an 
association with preclinical (70) or manifest atherosclerosis (71).  The presence of access 
type has a profound impact on the CRP level in dialysis patients (72). Albumin - 
historically viewed as a purely “nutritional” marker - is perhaps better viewed as a 
“negative acute phase” protein and known to correlate inversely with CRP (73, 74).  Low 
albumin is associated with increased mortality (75-77) and serum albumin is low in about 
half of the hemodialysis patients (78-80) despite what one would consider an “adequate” 
dialysis by Kt/V-based criteria. A substantial number of these patients have elevated CRP 
(81).  In summary, both serum albumin (82-85) and CRP (86-89) are known to correlate 
with inflammation and mortality in ESRD patients.  Unlike in the case of CRP, the 
implication of elevated cardiac troponins in this population is not well understood (88).  
Subtle troponin-I elevation has been associated with worse CV outcomes in ESRD and 
occasionally has been ascribed to the ESRD status alone.  Many of these patients with 
clinical symptoms (e.g., chest pains, shortness of breath or fever) will also receive 
measurements of commonly utilized biomarkers looking for myocardial damage and 
inflammation during Emergency Department (ED) evaluation. To what degree elevated 
troponin-I may reflect true myocardial damage or being a  sign of an underlying infection 
is not well-defined to date. 
 
1.7 The importance of vascular access catheters  
Vascular access dialysis catheters are life-saving during the care of dialysis 
patients when urgent RRT is needed and an arterio-venous (AV) fistula is not immediately 
available (90). While regular (non-tunneled) dual-lumen catheters can be used for the 
hospitalized patients, tunneled (occasionally referred to as “tunneled-cuffed”) dialysis 
catheters (TDC) are preferentially utilized in ambulatory settings (91). These catheters 
have the advantage of securing themselves into the subcutaneous tissue with a specific 
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type of polyethylene “cuff,” eliciting soft tissue growth and scarring while increasing the 
exit site’s resilience to infections (92). Nonetheless, they represent an inferior access 
modality (72, 93-96) and are linked to increased mortality (97-100) when compared with 
traditional AV fistulas or even AV grafts.  The Dialysis Outcomes and Practice Patterns 
Study (DOPPS) II has demonstrated that a 20% increase in the use of a dialysis unit 
catheter was associated with a 16% increase in mortality risk (101).  A later study 
confirmed that less frequent catheter and graft use is associated with improved patient 
survival (102). Bacterial colonization of these catheters is in fact common (103) and may 
adversely impact residual renal function (104) and sooner or later lead to manifest 
infectious events (105-107). In practical effect, the cumulative duration of the catheter 
itself represents the largest risk factor for a catheter infection (108, 109) and limiting the 
catheters’ presence to the shortest time possible requires the care provider’s vigilance and 
commitment. Up until now, the literature on long-term dialysis catheters was focused on 
circumstances of placement (110-112), optimizing patency and function (107, 113, 114), 
as well as prevention of infections (115-118).  On the other hand, circumstances and 
indications of TDC removal were less well understood or studied.  Historically, the 
removal of these catheters was felt to be a surgical or an interventionalist’s task and, up 
until recently, very little has been published on bedside removal of TDCs by non-
interventional nephrologists. 
 
1.8 Adherence 
Adherence (compliance) is a critical issue for successful care in dialysis patients.  
Adherence to dietary salt and water restrictions will influence weight gains and the 
stability of blood pressure, both during and off renal replacement therapy. Compliance 
with dietary restrictions would translate into IDWG, determining the ultrafiltration rate 
and, to large degree, the expected hemodynamic burden of the next hemodialysis session. 
Major variations exit among dialysis cohorts regarding adherence, perhaps best 
documented through the DOPPS (119), an international collaboration collecting data on 
care and practice patterns among Japanese, European and American dialysis patients. The 
DOPPS collected data on adverse prognostic markers (120), including phosphate control, 
IDWG and the number of unattended or significantly (≥10 minutes) shortened dialysis 
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sessions per month (119). In clinical practice, one has to realize that the relationship 
between mortality, morbidity and behavior is more closely related to shortened and non-
attended sessions than to the achieved control of phosphate and potassium (120, 121). 
Short but repetitive early terminations of HD sessions are not innocent events and can 
lead to adverse clinical outcomes (120, 122). Of concern are the Southern dialysis 
networks in the United States, having higher degrees of adverse outcomes despite 
improvements in overall healthcare delivery. Our own published experience from the 
Northwestern Louisiana found striking nonadherence the rule, rather than the exception: 
85.9% of patients shortened at least one hemodialysis session and 29% skipped at least 
one hemodialysis session per month (123). Repetitive volume overload will be associated 
with increased mortality and will lead to large changes in BP during dialysis sessions 
(124, 125). BP variability is known to be the highest on the first day of the week after the 
long, three-day period off RRT (126). Dialysis alone may not be the only answer and, 
perhaps not surprisingly, in the largest controlled trial to date (HEMO trial), those 
assigned to higher Kt/V (1.45 vs. 1.05) experienced more hypotensive episodes (18.3% 
versus 16.8%; p<0.001) (4). Compliance with the prescribed loop diuretic regimen helps 
to reduce IDWG between sessions (127, 128), further reducing the expected 
hemodynamic burden of net ultrafiltration during the following dialysis session. 
Additional potential maneuvers to decrease hemodynamic fluctuations include decreasing 
dialysis temperature (129) or, alternatively, increasing session lengths during RRTs (13).  
We could not gather affirmative evidence for anecdotal claims of excessive fluid intake 
precipitated by hot or humid weather in a relatively small, single-center study of 100 
patients from Central Europe (24). In summary, conclusions from large-scale studies may 
not be uniformly applicable to select subpopulations of patients (94, 102, 119, 130) and 
thus, local patterns of suboptimal treatment compliance impact hemodynamic stability 
and ultrafiltration (UF) burden during dialysis sessions. 
 
1.9 Definition of Acute Kidney Injury: limitations of serum creatinine  
The current classification theme of the acute impairment of renal function is 
heavily dependent on assessment of serum creatinine [Table 1]. However, the practical 
value of creatinine is much limited in the setting of positive fluid balances and dilutional 
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effects on creatinine (131-133) and different cut-off values may apply to start renal 
replacement technologies in critically ill. Volume overload, when massive, may 
completely mask the rise of serum creatinine and markedly underestimate the degree of 
renal functional impairment.  Chronically ill, wasted patients may have a low muscle mass 
and creatinine generation rate (134); on  the other hand, muscle injury and 
rhabdomyolysis may lead to disproportionate creatinine elevation in anuric subjects. 
Accordingly, interpretation of serum creatinine in critically ill may be markedly different 
from outpatients.  As we stated in our recent review paper highlighting limitations of 
measured serum creatinine in acute kidney injury (AKI), along with calculated glomerular 
filtration rate (GFR): 
“To some degree, the current thinking is captive to an era, viewing integrity of renal homeostasis 
as “kidney function percent”, a conceptual thought further reinforced by the emergence of 
automated glomerular filtration calculations (e.g., Modification of Diet in Renal Disease and 
CKD-EPI formula-based equations). When calculating fractional decline of renal function, only 
filtration is considered, assuming that decline of all other functions of the human kidney would 
be parallel to the decline of GFR - an assumption obviously not always taking place in terms of 
other indices, for instance, volume overload and hemodynamic status. Such thinking, however, 
applies even less to the setting of AKI in critically ill patients. As reasonable as progressive 
decline of GFR can be described in gradual CKD progression between the 15-60 mL/min/1.73 
m2 GFR range, clinical experience shows it to be inadequate when trying to define trigger points 
for clinical uremia in a catabolic state or need for RRT for volume-related indications.  Such 
thinking applies even less to the setting of AKI in volume overloaded or critically ill patients. 
An observed serum creatinine may have little relevance in a wasted subject with low muscle 
mass, generalized edema and prolonged respiratory failure with difficulty in weaning (134) 
Volume overload, when massive, may completely mask the rise of serum creatinine and/or 
markedly underestimates the degree of renal functional impairment.”(135)  
 
1.10 Fluid therapy in critically ill 
Since the early 2000s, early goal-directed therapy in sepsis has been the general rule 
(136), creating a practice pattern of aggressive volume resuscitation in Intensive Care 
Units (ICU) (137). However, an early study of successful goal-directed therapy to 
optimize mixed venous O2 saturation by Rivers et al. (138) was not replicated in 
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subsequent large, multi-center trials (139, 140). Volume load with isotonic saline 
promotes a non-anion gap metabolic acidosis, potentially contributing to increased 
mortality (141). Additionally, neither the use of albumin (142, 143), nor hydroxyethyl 
starch preparations (144-146) appear to be more effective than isotonic saline expansion 
alone. If anything, there is a potential for harm, including more RRT needed in 
hydroxyethyl starch recipients (147, 148). In comparison with historical approaches - 
which avoided bicarbonate administration - recent trends favor administering 
bicarbonate-containing fluids (149). Indeed, volume replacement with bicarbonate-
containing solutions resulted in a decreased occurrence of elevated creatinine and Risk-
Injury-Failure-Loss-End-Stage (RIFLE) staging “injury” or  “failure” stage in a 
prospective, in a prospective, open-label, sequential period pilot study from Australia 
(149), further supported by a systemic network meta-analysis in 2013 (148).  All these 
studies are raising the possibility that that fluid composition itself is less important than 
the degree of volume overload developing during a critical illness, especially in those 
with renal failure.  
 
1.11 Renal replacement therapy in Intensive Care Units  
Renal replacement therapy in ICUs continues to represent an ongoing clinical challenge, 
including the inherent difficulties identifying the “optimal” filling pressures for these 
patients. They represent an especially vulnerable group of patients with a high mortality 
rate, where AKI is particularly harmful when occurring as part of multi-organ failure 
(151, 152).  In those with volume-depleted state, early administration of sufficient IV 
volume replacement is critical to reverse tissue hypoperfusion and impact subsequent 
prognosis (138). Standard operating practice involves the administration of 20–30 
mL/body weight kg IV crystalloids over a 30-minute period, further repeated as 
necessary. However, over-aggressive volume resuscitation is also harmful and fluid 
overload has been associated with increased morbidity and mortality in patients with acute 
respiratory distress syndrome (153, 154), sepsis (155), in surgical ICU patients (156, 157) 
and those with abdominal compartment syndrome (158, 159). In a large observational 
clinical trial, persistently negative fluid balance was associated with improved outcomes 
during critical illness (mean daily fluid balance: -234 mL/day vs +560 mL/day among 
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non-survivors vs. survivors, p<0.0001) (160). Among children with renal failure, initial 
pediatric studies established that fluid overload at the initiation of continuous renal 
replacement therapy (CRRT) was associated with increased mortality (161-163). Among  
 
Table 1.  Kidney Disease Improving Global Outcomes (KDIGO) definition and 
classification of Acute Kidney Injury (AKI)(150) 
KDIGO 
Stagea 
Serum Creatinine Increase Urine Output Criteriad 
1 1.5–1.9 times baselinea or ≥0.3 mg/dl 
(≥26.5 mmol/L) increaseb 
<0.5 ml/kg per hour for 
6–12 h 
2 2–2.9 times baseline ≤0.5 ml/kg per hour for 
≥12 h 
3 3 times baseline or increase in serum 
creatinine ≥4 mg/dl (≥353.6 mmol/L) or 
initiation of renal replacement therapyc  
[in patients aged ≤18 years, decrease in 
estimated glomerular filtration rate to ≤35 
mL/min per 1.73 m2] 
≤0.3 ml/kg per hour for 
≥24 h or 
anuria ≥12 h 
 
aSerum creatinine increase is known or presumed to have occurred within the prior 7 days. 
bSerum creatinine to have occurred within any 48-hour period. 
cFor patients reaching stage 3 by serum creatinine >4 mg/dl, rather than require an acute 
rise ≥0.5 mg/dl over an unspecified time-period, KDIGO requires that the patient first 
achieve the creatinine-based change specified in the KDIGO AKI definition (either ≥0.3 
mg/dl within a 48-hour time window or an increase of ≥1.5 times baseline within 7 days). 
dUrine output criteria are identical to the corresponding risk/injury/failure/loss/end-stage 
(RIFLE) and Acute Kidney Injury Network (AKIN) stages. 
(Republished modified from Reference #150; Copyright has been obtained from 
American Journal of Kidney Disease and publisher Elsevier)  
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children with renal failure, initial pediatric studies established that fluid overload at the 
initiation of CRRT was associated with increased mortality (161-163). In adult ICU 
cohorts, AKI non-survivors had a more positive fluid balance than the non-survivors (164, 
165). On the other hand, the impact of the RRT in this context was not well studied until 
recently and it remains uncertain whether CRRT can meaningfully influence prognosis. 
In our former paper, we observed better outcomes in those with shorter wait-time before 
CRRT and in those with impaired baseline creatinine  (166). Further, the change in 
creatinine between admission and the initiation of CRRT (but not creatinine at initiation) 
was statistically different between survivors and non-survivors (1.6 vs. 2.6 mg/dL, 
p=0.023) (166). Unlike chronic RRT patients, critically ill renal patients are much more 
heterogeneous with an acute component of renal dysfunction, further complicating the 
interpretation of serum creatinine. The presence of an indwelling vascular catheter (rather 
than an AV fistula) is the rule, rather than an exception in these patients. In addition to 
the importance of time on RRT and hemodialysis access issues, the presence of comorbid 
fluid overload is another difficult clinical issue to address. Considering the above, there 
is a critical need to re-assess the impact of volume overload in critically ill patents, 
especially as it pertains to the trigger point of initiating RRT. 
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2. Objectives 
Certain clinical problems are both unique and pervasive in patients receiving 
RRT. These include volume overload, a frequent problem in ESRD patients on 
maintenance dialysis and a potential acute complication of AKI. Time is of the essence 
both during CRRT (maintaining integrity and patency of extracorporeal circuit) and 
during maintenance dialysis (prescription of appropriate duration of therapy to provide 
both uremic control and volume control) to minimize hemodynamic stress in these 
patients. Catheter use has remained prevalent and in fact escalated in dialysis patients 
over the last several years. Finally, the patients’ willingness to adopt the appropriate 
lifestyle as well as the dietary and time-commitment limitations remains the ultimate 
limiting factor for any prescribed medical regimen in ESRD.  These clinical concerns are 
not entirely independent of each other, but rather represent interrelated issues: e.g., dietary 
non-compliance leads to fluid overload and excessive UF during dialysis; the presence of 
a catheter leads to elevated inflammatory markers and poses the risk of infection, which 
in turn may lead to hypotension and excessive fluid resuscitation. My subsequent Ph.D. 
thesis examines my clinical research on several of these clinical concerns. 
 
2.1 Volume-related weight gain in the Intensive Care Units study 
Literature emerging around the middle of the first decade of the 21st century 
strongly suggested an adverse impact of volume overload in surgical settings for adults 
and in critically ill children with AKI. On the other hand, the impact of volume overload 
in adults with AKI was little explored at that time. Since fluid overload is associated with 
decreased survival in non-renal patients, we hypothesized that larger volume-related 
weight gain (VRWG) prior to RRT may be associated with higher mortality in critically 
ill AKI patients treated with CRRT (167). 
Specific research goals: 
1. To determine the degree of volume overload experienced in a cohort of critically 
ill patients before being started on CRRT. 
2. To examine the association of VRWG with subsequent outcomes in these 
critically ill patients. 
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2.2 Dialysis prescription and inflammatory markers on chronic hemodialysis study 
Unlike in AKI patients, the source of fluid overload in ESRD patients is not 
exogenous IV fluid but represents the dietary intake of both salt (sodium-chloride) and 
water. Time spent on maintenance dialysis, both for the patients and providers’ 
convenience, became progressively reduced in the era of high-flux dialyzers by the early 
2000s and time itself turned into a relatively neglected clinical parameter. Large and 
indiscriminate salt and water intake would lead to large IDWG, especially when time 
available for treatment is reduced. Under these circumstances, IDWG, hourly UF rate and 
time spent on renal dialysis represent a triangle of interconnected parameters, further 
determined by the patients’ compliance. Our initial review on the subjects suggested a 
potential adverse effect of reduced time in ESRD patients receiving maintenance RRT, 
including an impact on markers of inflammation, such as CRP and albumin (13). Since 
treatment time and ultrafiltration-rate (UFR) both correlate with patient survival (168), 
we hypothesized that long treatments with a slow UFR may also influence the control of 
inflammation on dialysis (169).  
Specific research goals: 
1. To examine the association of time on chronic hemodialysis on serum CRP and 
albumin. 
2. To examine the association of hourly UF rate on chronic hemodialysis with serum 
CRP and albumin levels. 
 
2.3 Bedside removal of permanent hemodialysis access catheters studies 
Permanent or semi-permanent (long-term) intravascular access catheters became 
routine from 1990 on and escalated in the last two decades in dialysis patients.  These 
foreign materials create a state of low-degree inflammation and contribute to excess 
infectious risk and mortality in ESRD patients (97-100). Since prolonged duration of 
TDCs represent profound risk factors for adverse outcomes, we wished to examine the 
circumstances, indications and clinical success rate of an emerging nephrology procedure, 
the bedside removal of these catheters.  Our study hypothesis was that bedside removal 
of TDC by a nephrologist is safe and effective, both for in- and outpatients and when 
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performed by physicians during graduate medical education training (114, 170). Our 
secondary objective was to examine the associations between select biomarkers (CRP, 
troponin-I) and clinical indications for TDC removals in our inpatient cohort (114). 
Specific research goals: 
1. To determine success rate with bedside removal of TDCs, including the safety and 
efficacy and complication rates of such procedure in both inpatient and outpatient 
settings. 
2. To examine the impact of vascular access catheters on certain serum biomarkers 
(CRP, troponin-I) in patients undergoing removal of these semi-permanent 
vascular access catheters. 
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3. Methods 
My proposed thesis will be supported by my existing publications on the subject 
(114, 167, 169, 170). Herewith, I would like to review the Materials and Methods of the 
studies I have utilized to develop this thesis, including one study examining the 
importance of volume-related weight gain before CRRT (Volume-Related Weight Gain 
and Subsequent Mortality in Acute Renal Failure Patients Treated with Continuous Renal 
Replacement Therapy. ASAIO Journal 2010 (Jul-Aug); 56(4): 333-7) (167), an another 
study examining the cross-sectional associations of inflammatory markers with treatment 
time during conventional hemodialysis (Correlation of Treatment Time and 
Ultrafiltration Rate with Serum Albumin and C-reactive Protein Levels in Patients with 
End Stage Kidney Disease Receiving Chronic Maintenance Hemodialysis: A Cross-
Sectional Study. Blood Purification 2010 (July); 30:8-15) (169) and two studies on TDC 
removal (The Safety and Efficacy of Bedside Removal of Tunneled Hemodialysis 
Catheters by Nephrology Trainees.  Renal Failure 2013 (October); 35 (9): 1264-1268; 
Tunneled Hemodialysis Catheter Removals by Non-Interventional Nephrologists: the 
University of Mississippi Experience. Seminars in Dialysis 2015 (Sept-Oct); 28(5): E48–
E52) (114, 170). The right to re-publish has been obtained from the journals and the 
publishers. Additionally, several other publications from our research groups will be 
reviewed or discussed, when appropriate. 
 
3.1 Volume-related weight gain study 
3.1.1 Study population  
We analyzed demographic, clinical and survival data from an observational, 
single-center registry of 81 patients treated with CRRT at the University of Mississippi 
Medical Center (UMMC), Jackson, MS (United States of America) over an 18-month 
period from January 2003 to June 2004. The study population consisted of all adult 
patients (age 18 or greater) with AKI admitted to the medical, cardiac, surgical, and 
cardiothoracic ICU of UMMC and treated with CRRT during the study’s period. After 
obtaining Institutional Review Board approval, the patients were prospectively enrolled 
into the study during or shortly after an initial nephrology consultation. A written consent 
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of participation was obtained from the patients or their immediate family. Indications for 
initiating CRRT included fluid overload and metabolic derangements refractory to 
conservative management, usually with associated hemodynamic instability. The timing 
and decision to initiate CRRT as well as the prescribed dose and modality of CRRT were 
at the discretion of the faculty attending nephrologist and the majority of the subjects 
received continuous veno-venous hemodiafiltration. All CRRT sessions were performed 
using Gambro Prisma (Gambro AB, Stockholm, Sweden) CRRT machines using AN-69 
polyacrylonitrile dialysis membranes.  Patients were excluded if they had preexisting 
ESRD or if the time from the onset of AKI to the initiation of CRRT was two weeks or 
greater.  The general characteristics of our study cohort and their association with 
mortality are shown in Table 2. and described in detail in our previous study (166). The 
principal outcome was mortality on day 30 (167). 
3.1.2 Definitions and variables of interest 
The patients were considered to have AKI if their serum creatinine increased by 
0.5 mg/dL (44.2 mol/L) or greater from baseline or if they had an abnormal serum 
creatinine at the presentation with no known baseline value.  Data on the patients’ 
creatinine level were collected at the initiation of CRRT. We also recorded the change in 
creatinine level from hospital admission to the initiation of CRRT and the dose of CRRT. 
The days waited were the number of days from the diagnosis of AKI to the initiation of 
CRRT (167). The patients’ weights were documented in a variety of settings: ED, regular 
nursing floors, and the ICUs; in all cases, the first documented weight available on the 
hospital record was taken as the initial weight; the majority of these was registered only 
in the ICUs. Standard hospital scales were used for the ambulatory patients and bed scales 
for the non-ambulatory or ICU patients.  Subsequent daily weights in ICUs were 
monitored with bed scales by the nursing staff of the unit and recorded on daily care 
charts.  In our study, we have defined VRWG as the difference between the initial (first 
available) weight and the weight at the initiation of CRRT.  Weight gain percentage (%) 
was interpreted as a difference in percentage between the initial weight and weight 
obtained at the initiation of CRRT.  Oliguria was not defined according to the current 
weight-based Acute Kidney Injury Network (AKIN) standard; instead, by an average 
urine output of less than 20 mL/hour for at least 12 hours before study enrollment.   
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Table 2. Baseline Characteristics of the University of Mississippi CRRT Cohort 
Stratified by Mortality (N = 81) (166) 
Baseline Characteristics 
means (SD) or % 
Survivors Death p 
 
Sample size 
   
All patients, n  40 41  
Baseline creatinine 
established, n 
 27 33  
Demographics    
Age, years  49.4 (16.7) 53.4 (16.6) 0.287 
Gender, female  12 (30.0%) 12 (29.3%) 0.943 
Apache IIa  26.7 (7.2) 28.4 (6.5) 0.271 
Creatinine (mg/dL)    
Baseline  1.4 (0.8) 1.1 (0.3) 0.088 
Admission  3.8 (3.5) 2.1 (1.9) 0.011 
CRRT initiation (InitCr)  5.3 (2.5) 4.8 (1.8) 0.304 
Change in creatinine (mg/dL)    
InitCr – Admission Cr  1.6 (1.9) 2.6 (1.9) 0.023 
InitCr – Baseline Cr  3.0 (2.0) 3.6 (1.6) 0.207 
% change in creatinineb    
InitCr – Admission Cr  165% (209) 223% (197) 0.214 
InitCr -  Baseline Cr  291% (243) 340% (174) 0.379 
CRRT dose 
(mL/kg/hour)c 
 21.1 (10.2) 24.5 (12.6) 0.187 
Days waitedd  3.2 (2.7) 4.2 (3.2) 0.137 
Sepsis  25 (61.0%) 23 (56.1%) 0.558 
ARF type    
Inpatient ARF  14 (43.8%) 18 (56.3%)  
Outpatient ARF  2 (16.7%) 10 (83.3%)  
ARF on Chronic Kidney 
Disease 
 11 (68.8%) 5 (31.3%)  
ICU service type   0.205 
Surgical ICU  9 (22.5%) 7 (17.1%)  
Cardiothoracic ICU  10 (25%) 4 (9.8%)  
Cardiology ICU  3 (7.5%) 6 (14.6%)  
Medical ICU  18 (45%) 24 (58.8%) 
 
 
The conversion factor for serum creatinine in mg/dL to mol/L is 88.4. 
Abbreviations: ARF, acute renal failure; Cr, creatinine; CRRT, continuous renal 
replacement therapy; ICU, Intensive Care Unit; InitCr, creatinine at CRRT initiation 
aApache II scores were calculated at time of renal consult. 
bPercent change in creatinine was computed by either 100% x (InitCr -  
AdmCr)/AdmCr or 100% x (InitCr - BLCr)/BLCr. 
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cCRRT was the prescribed CRRT dose in mL/kg/hour. Continuous veno-venous 
hemofiltration was prescribed pre-filter dosing. 
dDays waited was the number of days from first 0.5 mg/dL elevation in serum 
creatinine to initiation of CRRT. 
 
The diagnosis of sepsis was a clinical diagnosis as stated on the medical record and Acute 
Physiology and Chronic Health Evaluation Apache II scores were calculated at the time 
of the renal consult was obtained (167).  
3.1.3 Statistical methods 
Data on patient characteristics are shown as mean ±standard deviation (SD) for 
continuous variables or percentages for categorical variables.  The primary goal of the 
study was to examine the effect of various cut-off net fluid accumulations, that is VRWG 
≥10% or ≥20% and oliguria as variables associated with mortality.  VRWG ≥10% patients 
were compared to those that gained <10%. In a separate analysis, those who gained ≥20% 
were compared to those gaining < 20%, <10% or between ≥10 and <20%.  Additional 
variables included age, sex, chart diagnosis of sepsis, Apache II scores, CRRT dose, 
creatinine level at the initiation of CRRT, absolute change form of creatinine, days waited 
and ICU location.  A cross-sectional analysis of selected variables was conducted to 
identify correlates with mortality. Chi-square tests were used for bivariate analyses of 
correlations between selected variables and mortality. Independent t-tests were performed 
to assess the correlations of continuous variables with mortality. Multivariate logistic 
analyses were conducted for more complex correlations. The data were analyzed using 
SPSS version 16 (SPSS Inc., Chicago, IL) and Minitab (version 13; Minitab Inc., State 
College, PA) (167).  
 
3.2 Dialysis prescription and inflammatory markers on dialysis study  
3.2.1 Study population 
We have undertaken a cross-sectional study in a network of 12 hemodialysis 
centers including all Diaverum Hemodialysis Units in Hungary and the University of 
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Mississippi Medical Center outpatient hemodialysis unit in Jackson, Mississippi, USA.  
All patients receiving in-center maintenance hemodialysis three times a week were 
recruited for the study.  Dialysis centers collected data from patient charts and local 
databases originally established for purposes of quality control.  Patient- and dialysis-
related characteristics, comorbidity diagnoses, acute events, medication use, and other 
covariates were extracted in July, 2007.  The study was approved by the UMMC Human 
Research Office and the Office of Scientific Officer of Diaverum, Inc (169). 
3.2.2 Definitions and variables of interest 
Age was the number of full calendar years completed since birth.  Sex was self-
reported and either male or female.  Ethnicity was either Caucasian or African American.  
Comorbid conditions, such as diabetes mellitus, coronary artery disease, congestive heart 
failure (CHF) and human immunodeficiency-virus (HIV) positive state were recorded if 
listed in the medical records.  Medical records were updated within the month of data 
collection.  The dialysis vintage was the number of completed months since starting renal 
replacement therapy on dialysis.  EDW was the physician-prescribed ideal weight.  Kt/V 
was defined as the single-pool urea clearance reported by the dialysis provider health 
information network.  An acute infectious or coronary event was acknowledged based on 
the medical record during the index month.  The presence of residual renal function (RRF) 
was defined as evidence of at least 200 mL urinary output in a 24-hour urine collection 
within 3 months of July, 2007.  Treatment time was defined as the average length of 
dialysis sessions in minutes recorded during the index month.  The UF rate was defined 
as the hourly volume removed in mL per kg of body weight (mL/kg/hour) according to 
the DOPPS (168) and averaged over the index month.  Serum albumin and CRP were 
measured as part of the routine care.  Albumin was measured by Bromocresol green 
methods (Diagnosticum Zrt., Hungary; Spectra Laboratories, USA) and reported in gm/L 
or gm/dL.  CRP was measured by immunoturbidimetric assay and reported as either < 5 
mg/L, any numerical value above 5 mg/L (Spectra Laboratories, USA) or numerical 
values both below and above 5 mg/L (APTEC, Belgium) (169). 
3.2.3 Statistical methods 
Data on patient characteristics are shown as mean ±SD for continuous variables or 
percentages for categorical variables.  Serum albumin and CRP were used as continuous 
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variables in the analysis of covariance (ANCOVA) models and categorized as bivariate 
during logistic regression.  In our study, we dichotomized a priori albumin values at 40 
gm/L (approximate mid-normal range value) with albumin > 40 gm/L designated as a 
favorable outcome for purposes of logistic regression analysis; conversely, albumin ≤ 40 
gm/L was designated as low albumin or failure to reach normal albumin levels.  Similarly, 
CRP was dichotomized at 5 mg/L, with CRP ≤ 5 mg/L being designated as a favorable 
outcome, CRP > 5 mg/L as failure.  Potential factors associated with inflammation were 
tested in Analysis of Covariance (ANCOVA) models.  An initial model of 23 variables 
included age, sex, ethnicity, vascular access, dialysis vintage, RRF, dry weight, 
comorbidities, medications (statins, aspirin, vitamin-D analogues, phosphate binders, 
calcimimetic), Kt/V, type of dialyzer, treatment time and UF rate.  These parameters are 
otherwise identical to the ones listed in Table 3. (169).  In a subsequent analysis, the initial 
set has been narrowed down to 15 variables as follows: age, sex, ethnicity, vascular access 
type, dialysis vintage, dry weight, diabetes mellitus, coronary artery disease, CHF, HIV 
infection, acute coronary event, acute infectious event, Kt/V, treatment time and UF rate.  
Logistic regression models were constructed to calculate Odds Ratio (OR) with 95% 
confidence intervals (CI) predicting favorable outcomes of CRP and albumin.  Treatment 
time was dichotomized at four hours and entered into logistic regression modeling as a 
categorical variable of > 4 hours for “long” treatment time and ≤ 4 hours for “short” 
treatment time.  The initial logistic regression model operated with the same 15 
independent variables as the second ANCOVA model.  Stepwise selection was applied in 
logistic regression modeling to assess the individual contribution of major predictors.  As 
neither of the dependent parameters were found to be normally distributed, the non-
parametric Mann-Whitney test was also utilized to establish ranks between longer than 4-
hour treatment time and less than 10 mL/kg/h UF rate with favorable outcome in serum 
albumin and CRP levels.  All statistical analyses were performed using SPSS 16 (SPSS 
Inc., Chicago, IL) (169). 
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Table 3.  Population and treatment characteristics (169) 
 
Demographic characteristics:  
All data/partial missing data: 616 / 103 
Age (years):  60.9 ±14.4 
Gender (M/F) % 52.1% / 47.9% 
Ethnicity (African-American/Caucasian) % 18.2% / 81.8% 
Vascular Access (NF/TDC/TC/AVG)* %  67.0% / 19.3% / 7.6% / 6.0% 
Dialysis Vintage (months): 46.2 ±44.8 
Residual Renal Function (≥ 200 mL) %: 57.6% 
Estimated Dry Weight (kg): 72.3 ±17.3 
 
Comorbidities:  
Percent of patients having comorbidity  (n=616)  
Diabetes Mellitus 35.2% 
Coronary Artery Disease 19.3% 
Congestive Heart Failure 43.7% 
HIV** Infection   1.3% 
Active Smoking 24.5% 
Acute Coronary Event   4.7% 
Acute Infectious Event 12.9% 
 
Dialysis treatment characteristics:  
Treatment Time (min) 237.3 ±23.8 
Ultrafiltration Rate (mL/kg/hour) 7.05 ±4.05 
Kt/V: 1.50 ±0.34 
Dialyzer***:  F-180NR or F200NR in 1 center 
vs.   
Polyflux 17 or Polyflux 21 in 11 
centers 
 
***Choice of dialyzer and ethnicity almost completely overlapped 
Medications:  
Percent of patients taking medication (n=616):  
Statins (HMG-CoA reductase inhibitors) 26.3% 
Aspirin 40.2% 
Calcitriol or Vitamin-D analogues 46.8% 
Phosphate binders  69.0% 
Calcimimetic   5.1% 
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Table 3.  Population and treatment characteristics – continued 
Clinical outcomes: serum albumin and CRP: 
Mean values:  
Serum albumin (gm/L): 39.8 ±4.6 
C-reactive protein (mg/L): 12.7 ±18.2 
Favorable outcomes observed (%):  
Serum albumin ≥ 40 gm/L: 57.7% 
C-reactive protein ≤ 5 mg/L: 40.9% 
*Abbreviations: NF/TDC/TC/AVG=native fistula/tunneled dialysis 
catheter/temporary catheter/synthetic graft; **HIV=Human immunodeficiency virus. 
 
3.3 Vascular catheter access removal studies 
3.3.1 Study population 
Our catheter removal experience consisted of two studies, Study A (114) and 
Study B (170). Study A consisted of a retrospective cohort of a consecutive 3-year bedside 
TDC removal experience among hospitalized subjects at the University of Mississippi 
Medical Center performed via the Nephrology Consult Service (January 01, 2007 to 
December 31, 2009) (114). Study B consisted of a review of mixed inpatient and 
outpatient bedside TDC removals from January 1, 2010 to June 30, 2013, over a 3 ½ year 
period at the Nephrology Division of the University of Mississippi Medical Center (170). 
In study A, patients had been referred to the procedure team by nephrology consulting 
teams whenever TDC removal became medically necessary in the team’s clinical 
judgment. In Study B, subjects had been referred to the author of the present thesis via 
nephrology providers from a variety of settings: ED, general inpatient floor, ICUs or 
ambulatory outpatient sections. In both studies, the decision to remove the TDC was made 
solely by the patients’ nephrology attending physician for a variety of reasons, including 
proven bacteremia, fever or clinical septic state, catheter malfunction or recovery of renal 
function. Additionally, in study B, access maturation was also considered as a reason for 
TDC removal. The basis of data recovery was the procedure teaching and procedure log 
of the author of the present thesis, which included all inpatient TDC removals by the 
Nephrology Division for study A and most of the outpatient removal at bedside for study 
B. In the cases of inpatient TDC removals, these took place in the patients’ room on the 
nursing floor; for outpatient removals, we utilized rooms specifically reserved for 
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procedures in the outpatient dialysis unit. Some but not all procedures involved renal 
trainees, as well. For inpatient procedures, the TDC removal always took place on the 
same day when the decision to remove the catheter was made (114, 170). 
3.3.2 Definitions and variables of interest 
For study A (114), we reviewed and collected data on multiple patient-related 
variables: age, ethnicity, sex and highest blood urea nitrogen, creatinine and blood 
coagulation tests within 24 hours of the procedure. Age was the number of full calendar 
years completed since birth.  Sex was self-reported as either male or female.  Ethnicity 
was either Caucasian or African American. Additionally, we collected data on certain 
other peri-procedure parameters up to three days before and after the procedure which 
consisted of peak and nadir white blood cell count (WBC); nadir hemoglobin, nadir 
platelet count and vital signs (temperature, heart rate, blood pressure). Two additional 
biochemical parameters associated with inflammation and myocardial stress, CRP and 
troponin-I were searched for and recovered from medical records, if available within 48 
hours of TDC removal.  Procedure-related variables, which included the indication for 
the procedure, the site and location of removal and any complications or difficulties 
during the procedure were recorded from the teaching log of the author of the present 
thesis (114).  For study B (170), we collected data on similar variables, but within three 
days before and after the procedure: highest blood urea nitrogen, creatinine, and blood 
coagulation tests; peak WBC count; nadir hemoglobin and platelet count (when 
available). Demographic definitions (age, sex and ethnicity) were identical to study A.  
As a rule, we did not require a complete blood count (CBC) or standard tests of blood 
coagulation with prothrombin time (PT) and activated partial thromboplastin time (aPTT) 
before outpatient removals.  However, we routinely obtained PT/aPTT among inpatients 
if not already available within 3 days (170).   
Full technical details of the procedure are discussed in the following section as 
described in our original publications (114, 170, 171), our recent review (172) and can be 
viewed on YouTube video link (173). Contraindications for the procedure included 
abnormal coagulation results, including prothrombin time PT International Normalized 
Ratio (INR) >1.5 and markedly decreased platelet count (<60,000/mm3), when otherwise 
correctable.  No further selection criteria were applied beyond the above-mentioned 
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exclusion criteria. All patients provided written consents before the procedure. Both 
Study A and Study B were reviewed and approved by the UMMC Human Research Office 
(Institutional Review Board) (114, 170). 
3.3.3 Statistical methods 
Upon review of both electronic and paper-based medical records, pre-defined 
information was collected in Microsoft Excel data sheets.  Data were analyzed using 
SPSS Statistics 19 (IBM Corporation, Armonk, NY) and reported with means ±SD or 
medians 25-75% interquartile range (IQR) for descriptive data; Pearson’s correlation and 
chi-square as well as independent-samples t-test were utilized for statistical comparisons 
(114, 170).  
3.3.4 Procedure description for Tunneled Dialysis Catheter removal 
“Preparation for the procedure included obtaining informed consent in writing from the patient 
or next-of-kin and gathering the limited supplies needed in the patient’s care room or the dialysis 
clinic procedure room: suture removal kit, syringes, needles, 1% lidocaine, face mask, sterile 
gown, sterile gloves, sterile gauze dressing, vascular clamp, chlorhexidine cleaning swabs and 
dressing tape. Examples of preparation tray are shown in Photo 1. Before starting the procedure, 
we carefully ascertain the exact location of the retaining subcutaneous “cuff”, both by visual 
inspection and gentle palpation over the subcutaneous tract of the of hardware. If uncertainty 
about the cuff location persisted, one could also apply a “twist” along the axis of the catheter to 
identify the retention point of the cuff. Sutures if present were removed after cleaning. 
Subsequently the catheter exit area, the surrounding skin and the catheter proximal to the hub 
(including the buried, but mobile portion distal to the Dacron cuff) are carefully cleaned with 
chlorhexidine-based cleaning solution […]  Local anesthesia is achieved with subcutaneous 
infiltration of 10-15 mL of 1% lidocaine hydrochloride of the surrounding tissues. Afterwards, 
the cleaned area is draped to create a sterile field for dissection, with additional sterile towel 
used to wrap around and cover the extracorporeal parts of the catheter. Thereafter, the 
subcutaneous tissues around the catheter up to the cuff, as well as an additional 2-3 cm 
proximally are bluntly dissected with a hemostat clamp, to achieve mobilization of the catheter 
from the surrounding soft tissues. Ideal dissection is achieved by repeatedly inserting the sterile 
hemostat in all four quadrants around the catheter - that is, above, below, to the right and to the 
left to it - and opening up the clamp’s tip to a width of at least 2 cm. The minimal length of 
vascular clamp necessary for the procedure would be 15-20 cm, preferentially a straight one. 
Once the cuff and the catheter are free from all connective tissue, the TDC could be pulled with 
DOI:10.14753/SE.2018.2065
33 
 
a controlled amount of force. During removal, the exit site is covered with sterile gauze and 
gentle hand pressure is applied to prevent aerosolizing of blood during removal. Hemostasis is 
obtained by the application of direct pressure on the tract and the exit site with a sterile gauze 
for 5 minutes or until no bleeding was detectable, whichever is longer; thereafter, a fairly tight 
dressing is placed until the next morning. […] The total procedure time is usually between 15-
20 minutes and we also routinely ask outpatients to stay in the clinic waiting area for at least 30 
min after the end of the procedure. For the newly placed catheters (<7-10 days), usually no 
dissection is needed and most of the catheters can be smoothly pulled after removing of the 
sutures.”(172) 
 
 
Photo 1.: Sample TDC removal preparation tray at UMMC 
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4. Results 
4.1 Volume-related weight gain in critically ill patients with AKI and subsequent 
mortality  
For our study, the mean age of the 81 patients meeting the inclusion criteria was 
51.4 ±16.7 years (range: 23-85), 24 of which were female (30%). The overall raw 
mortality rate for the cohort was 50.6%.  Mean VRWG was 8.3 ±9.6 kg but with a wide 
range of variation observed in the cohort (range: -10.5 to +45.9 kg).  The mean percent 
weight gain was 10.2 ±13.5% (range: -11 to +81%).  Oliguria was present in 53 patients 
before RRT commenced (65.4%).  We have not observed significant associations between 
Apache II scores and weight changes (p=0.368), chart diagnosis of sepsis and death 
(p=0.653), or sex and death (p=1.00) in the course of the univariate analysis. Thirty-eight 
patients (46.9%) had VRWG ≥10% and thirteen patients (16%) had ≥20% VRWG.  
WRVG ≥10% (p=0.046) and oliguria (p=0.020) were significantly associated with death. 
The basic cohort demographics stratified by the two major cut-off categories are 
presented in two separate Tables: VRWG of <10% and ≥10% are presented in Table 4. 
while VRWG >20% and ≥20% are presented in Table 5. (167). Differences have been 
observed between the groups with VRWG <10% and ≥10% (creatinine at CRRT 
initiation, CRRT dose and days waited for CRRT) but these did not persist when the 
cohort was separated according to VRWG >20% and ≥20%.  Female subjects were less 
likely to experience WRWG ≥20% (167).  
We observed that patients with a VRWG ≥10% had a significantly higher risk of 
dying then the reference group of <10% (OR 2.62, 95% CI: 1.07-6.44; p=0.046) (Figure 
1.1).  When the patients were stratified using 20% VRWG as the cut-off point, the odds 
ratio for death in the patients with VRWG ≥20% was even higher, compared with the 
patients with VRWG <20% (OR 3.98, 95% CI: 1.01-15.75) albeit nominal significance 
was lost (p=0.067) (Figure 1.2) (167). As shown in Figure 2, separating the cohort into 
three categories of VRWG (<10%; ≥10 but <20%; ≥20%) was associated with a stepwise 
progressive increase of mortality: 39.5% (17 of 43), 56% (14 of 25) and 76.9% (10 of 
13).  Accordingly, against a reference group of VRWG <10%, OR for death was increased 
to 1.95 (95% CI: 0.72–5.28; p = 0.191) in the group with intermediate weight gains (≥10 
but <20%) and to 5.10 (95% CI: 1.22–21.25; p = 0.025) in the group with 
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 Table 4. Clinical Variables and Outcomes in Patients  
with VRWGs of <10% vs. ≥10% (167) 
 
 
 
 
 
 
Clinical Variables  All  VRWG<10% 
<10% 10% 
VRWG≥10%  
≥10% 10% 
p 
     Number 81 43  38 N/A 
Average weight gain (%)  1.4 ±4.6 20.3 ±13.3  
Age (years)  50.4 ±16.5 52.6 ±17 0.547 
Female Sex  27.9% 31.5% 0.718 
Apache II scores  27.2 ±6.9 27.9 ±6.8 0.657 
Creatinine at CRRT initiation 
(mg/dL) (mg/dL) 
 5.5 ±2.4 4.5 ±1.8 0.039 
Change in creatinine (mg/dL)  1.8 ±2.2 2.4 ±1.7 0.167 
Days elapsed until CRRT  3.1 ±2.9 4.4 ±3 0.061 
Sepsis  55.8% 63.1% 0.500 
Oliguria  62.8% 68.4% 0.593 
ICU Service    0.192 
   Cardiology ICU (n=9)  16.3% 5.3%  
   Cardiac ICU-Surgery (n=14)  11.7% 23.7%  
   Medical ICU (n=42)  55.8% 47.4%  
   Surgical ICU (n=16)  16.3% 23.7%  
Mortality 50.6%  39.5% 63.2% 0.029 
 
Abbreviations: CRRT = continuous renal replacement therapy; ICU = intensive 
care unit; VRWG = volume-related weight gain 
Apache II scores were calculated at time of renal consult. The conversion factor 
for serum creatinine in mg/dL to mol/L is 88.4  
 
severe (≥20%) weight gains. Of the forty-one deceased patients 32 had oliguria with an 
unadjusted OR of death 3.22 (95% CI: 1.23-8.45, p=0.02) for oliguria (167).  Finally, we 
performed a multivariate modeling to assess the correlations of other potential risk factors 
for death in these patients. When analyzed together, both oliguria (p=0.021) and ≥10 
weight gain (p=0.042) maintained independent significance. When sepsis and Apache II 
scores were included in the modeling, once again, oliguria (OR 3.04, p=0.032) and ≥10% 
weight gain (OR 2.71, p=0.040) maintained significance in the more complex modeling 
[Table 6.1-2.]. 
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Table 5. Clinical Variables and Outcomes in Patients  
with VRWG of <20% vs. ≥20% (167) 
Clinical Variables  All VRWG<20% 
<20% 
VRWG≥20% 
≥20% 
p  
value 
     Number 81 68 13 n/a 
Average VRWG (%)  6.0 ±7.4 32.2 ±17.1  
Age (years)  51.9 ±16.7 49.2 ±17 0.61
6 
Female Sex  23.5% 61.5% 0.00
8 
Apache II scores  27.3 ±6.8 28.8 ±7.2 0.48
0 
Creatinine at CRRT initiation 
ininitiinitiation (mg/dL) 
(mg/dL) 
 5.2 ±2.2 4.2 ±1.6 0.05
8 
Change in creatinine (mg/dL)  2.0 ±2.0 2.5 ±1.5 0.33
4 
Days elapsed until CRRT  3.5 ±2.9 4.7 ±3.1 0.24
1 
Sepsis  57.4% 69.2% 0.40
1 
Oliguria  63.2% 76.9% 0.29
5 
ICU Service    0.54
6 
   Cardiology ICU (n=9) 
ICCardiologyCardiology (n=9) 
 10.3% 15.4%  
   Cardiac ICU-Surgery (n=14)  19.1% 7.7%  
   Medical ICU (n=42)  52.9% 46.2%  
   Surgical ICU (n=16)  17.6% 30.8%  
Mortality 50.6
% 
45.6% 76.9% 0.01
7 
 
Abbreviations: CRRT = continuous renal replacement therapy; ICU = intensive care 
unit; VRWG = volume-related weight gain 
Apache II scores were calculated at time of renal consult. The conversion factor for 
serum creatinine in mg/dL to mmol/L is 88.4 
 
The effect of sepsis and Apache II scores remained non-significant on multivariate 
analysis. Altogether, the combined presence of oliguria and ≥10% weight gain explained 
approximately 12% of the observed mortality.  Including into the logistic regression 
model creatinine level at CRRT initiation, CRRT dose and days waited for CRRT 
abolished the association of mortality with VRWG ≥10% (p=0.196; OR 0.71-5.29), but 
not with oliguria (OR 3.94; 95% CI 1.37-11.37; p=0.011), with minimal improvement of 
the model’s overall predictability (R2 0.16) (167).  Analyzing our data through a three-
way separation of the cohort (VRWG < 10%; ≥10 but <20%; ≥20%) in logistic regression, 
the OR of mortality increased 2.17 (95% CI: 1.11-4.26; p=0.024) for each categorical 
change of VRWG.   
DOI:10.14753/SE.2018.2065
37 
 
 
 
Figure 1.1 and 1.2. Association between VRWG and Mortality at different cut-offs of 
VRWG 
Abbreviations: VRWG = volume-related weight gain; Wt gain: weight gain 
 
 
 
0
20
40
60
80
100
*
*
Wt Gain
<10%
Wt Gain
>10% but <20%
Wt Gain
>20%
M
o
rt
a
li
ty
 %
 
Figure 2. Association between progressive increases in VRWG and Mortality (167) 
Asterisk (*) indicating statistical significance (p<0.05) 
Abbreviations: VRWG = volume-related weight gain; Wt gain: weight gain 
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The effect of oliguria also remained significant: OR 2.17 (1.06-8.11; p=0.038); however, 
Apache II (p=0.239) and sepsis (p=0.352) did not.  Including creatinine in the logistic 
regression model at CRRT initiation, CRRT dose, and days waited did not show an 
independent association with death for either one (p=0.322, 0.584, 0.163, respectively), 
but abolished the association of VRWG with death (p=0.125; OR 0.86-3.51), while the 
association with oliguria persisted (OR 3.80; 95% CI 1.31-11.01; p=0.014) (167).  As 
larger VRWG was also associated with lower serum creatinine (5.5 ±2.4 mg/dL vs. 4.5 
±1.8 mg/dL with lower creatinine in VRWG≥10%; p=0.039), adjusting for creatinine at 
CRRT start may have resulted in simultaneous adjustment for larger fluid gains, as well, 
in those with larger fluid gains and dilution of serum creatinine. With the inclusion of 
multiple covariates (all the above), the results remained virtually unchanged.  Finally, we 
analyzed the OR between the two extreme ends of our cohort: those gaining VRWG 
<10% vs. those with VRWG ≥20% (a total of 56 subjects) excluding the “intermediate” 
cohort (VRWG ≥10% but <20%) in multiple logistic regression models.  With the 
inclusion of oliguria, CRRT dose, creatinine at CRRT initiation, and days waited, the OR 
for death (≥20% vs. <10% VRWG) was 4.34 and now approached significance: p=0.069 
(OR 0.89 – 21.16).  Further, results with the inclusion of multiple covariate results were 
similar, as shown in Table 7. (167). 
 
Table 6.1 The Combined Effect of Oliguria and VRWG  
During Multivariate Modeling (167) 
Clinical Variable 
exp (B) ±95%  
Confidence Intervals 
p-value R2 
    Oliguria and ≥10% Volume-Related Weight Gain 
Oliguria 3.23 (1.19-8.73) 0.021 
0.12 
≥10% VRWG 2.64 (1.04-6.70) 0.042 
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Table 6.2.  The Effect of Oliguria, VRWG, Sepsis, and Apache II Scores on 
Mortality During Multivariate Modeling 
Oliguria, ≥10% Volume-Related Weight Gain, Sepsis and Apache II scores  
Oliguria 3.04 (1.10-8.36) 0.032 
0.13 
≥10% VRWG 2.71 (1.05-6.99) 0.040 
Sepsis 0.63 (0.22-1.78) 0.379 
Apache II scores 0.96 (0.89-1.03) 0.219 
 
Abbreviations: VRWG = volume-related weight gain 
 
 
Table 7. The Effect of VRWGs (<10% vs. ≥20%) on Mortality During Multivariate 
Modeling (167) 
Clinical Variable 
exp (B) ±95%  
Confidence Intervals 
p-value 
Oliguria 1.90 (0.53-6.80) 0.325 
VRWGs (<10% vs. ≥20%) 4.03 (0.88-18.38) 0.072 
Sepsis 
0.64 (0.18-2.27) 0.490 
Apache II scores 1.02 (0.94-1.12) 0.605 
Creatinine at CRRT initiation (mg/dL) 0.92 (0.71-1.20) 0.553 
Days elapsed until CRRT 1.10 (0.90-1.36) 0.353 
Overall R2 = 0.147. 
Abbreviations: VRWG = volume-related weight gain 
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4.2 Dialysis prescription and inflammatory markers during conventional 
hemodialysis  
Of the 626 reviewed patients, 616 (98.4%) met our inclusion criteria for 
undergoing maintenance hemodialysis three times a week in the 12 participating centers 
and having at least one of the critical data (albumin or CRP) obtained during the data 
collection period available for further analysis. Patient- and treatment-specific 
characteristics of these 616 participants are summarized in Table 3. (169).  Mean age for 
the cohort was 60.9 ±14.4 years with an overall dialysis vintage of 46.16 ±44.8 months.  
Racial distribution of patients was 408 (79%) Caucasian and 105 (21%) African 
American and there was a large burden of diabetes mellitus (35%), congestive heart 
failure (44%) and coronary artery disease (19%) among the participants. Significant RRF 
(≥200 mL) was present in over half (58%) of the population.  The average treatment time 
(237.3 ±23.8 minutes) was comparable to the European average at the time the research 
was taking place and about 16 minutes longer than the US average reported by DOPPS 
(168).   Altogether, 122 (19.8%) patients were dialyzed for longer than 4 hours and 494 
(80.2%) for less than or equal to 4 hours; mean treatment time for these was 269.7 ±14 
and 229.3 ±18 minutes, respectively.  However, mean treatment time did not significantly 
differ between the European (237.6 ±24 minutes) and the US arm (236.4 ±21.6 minutes) 
of the cohort.  Mean UF rate (7.05 ±4.05 mL/kg/h) was the lowest in all DOPPS regions 
(168).  There was no statistically significant univariate association between treatment 
time and UF rate (Pearson r: -0.042; p=0.222).  Both CRP and serum albumin were 
distributed non-normally. CRP was available for 616 (100%) participants but albumin for 
only 522 (84.7%).  Mean serum albumin was close to 40 gm/L with 301 (57.7 %) patients 
exceeding this level (169).  The distribution of serum albumin values by treatment time 
and UF rate is shown in Figure 3. and Figure 4., respectively (169).  
 CRP was highly variable with a wide range (undetectable to 146.8 mg/L) and ≤5 
mg/L in 252 (41%) of the cohort. The covariates of the initial ANCOVA model were the 
same as the patient- and treatment-specific characteristics in Table 3. However, the type 
of the dialyzer could not be analyzed separately due to an almost complete overlap of the 
choice of the dialyzer and African American ethnicity.  In the initial screening ANCOVA 
model, only ethnicity (p=0.0036) and acute infection (p=0.0002) were significantly 
associated with serum albumin, and only vascular access type (p=0.009), acute coronary 
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event (p=0.0459) and acute infection (p<0.0001) were associated with CRP.  Analyzing 
the set of 15 variables [Table 8.1], serum albumin as a continuous variable was 
significantly associated with ethnicity, dry weight, HIV status, acute infection and 
treatment time.  In the case of CRP [Table 8.2], a significant association was found with 
vascular access type, dialysis vintage and acute infection while associations with acute 
coronary events were no longer significant (169).   
 
 
 
Figure 3.  Distribution of serum albumin by treatment time  (169) 
Abbreviation: HD= hemodialysis 
Mean albumin levels were 39.4 ±4.69 g/L among subjects receiving “short” (≤4 hours) 
treatment and 41.62 ±3.39 gm/L among those receiving “long” treatment (>4 hours).  
Stepwise selection was applied in logistic regression modeling to assess the individual  
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Figure 4.  Distribution of serum albumin by ultrafiltration rate (UFR) (169) 
Abbreviations: UFR = ultrafiltration rate 
contribution of major predictors.  For albumin, failure to reach more than 40 g/L in Step 
1 correlated with short treatment time, Caucasian ethnicity, lower dry weight and the 
presence of an acute infection [Table 9.] (169). On the other hand, UF rate was not found 
to be a significant correlate of failure to reach > 40 gm/L albumin.   
After Step 4, a treatment time of longer than 4 hours was associated with 
decreased odds of low albumin (OR 0.397, 95% CI: 0.235-0.672; p<0.001). Being 
Caucasian increased the likelihood of failing to reach the albumin target (OR 2.304, 95% 
CI: 1.462-3.630; p<0.0001), as did acute infection (OR 2.240, 95% CI: 1.327-3.780; 
p=0.003).  Dialysis vintage had only borderline significance (OR 0.995, 95% CI: 0.991-
1.000; p=0.041) while dry weight was not significant (169). When additional subcohort 
analysis was performed according to ethnicity (Caucasian vs. African American), 
treatment time greater than 4 hours once again reduced the risk of having low albumin 
(OR 0.385, 95% CI: 0.197-0.683, p=0.002) among the 408 Caucasians.  However, the 
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effect of treatment time among African Americans was no longer significant (p=0.105), 
likely due to the limited number of these subjects (n=105) (169).  Separating CRP 
according to treatment time, mean CRP in the short-treatment cohort was 12.05 ±18.78 
mg/L and 11.23 ±15.62 mg/L in the long-treatment-time subgroup.  Logistic regression 
demonstrated that factors correlating with high CRP were age, congestive heart failure 
(CHF), lower dry weight and vascular access type [Table 10.] (169). During stepwise 
selection, only the presence of CHF (OR 1.634, 95% CI: 1.154-2.312; p=0.006) and acute 
infection (OR 1.799, 95% CI: 1.059-3.056, p=0.03) remained positive correlates of a high 
CRP level.  The significance of age decreased (OR 1.014, 95% CI 1.002-1.026; p=0.02) 
while dry weight and vascular access type lost significance.  UF rate was not found to be 
a significant correlate of either main outcomes  (169).   
 
Abbreviations: HIV = human immunodeficiency virus; ANCOVA = analysis of 
covariance 
 
 
Table 8.1 – 8.2.  (169) 
 
 
Table 8.1.  ANCOVA analysis for 
serum albumin 
Table 8.2. ANCOVA analysis for C-
reactive protein 
Predictor variable Significance (p) Predictor variable Significance (p) 
Age 0.292 Age 0.126 
Gender 0.512 Gender 0.215 
Ethnicity 0.001 Ethnicity 0.973 
Vascular Access  0.085 Vascular Access 0.002 
Dialysis Vintage 0.759 Dialysis Vintage 0.017 
Dry Weight 0.034 Dry Weight 0.239 
Diabetes Mellitus 0.108 Diabetes Mellitus 0.190 
Coronary Artery 
Disease 
0.266 
Coronary Artery 
Disease 
0.410 
Congestive Heart 
Failure 
0.169 
Congestive Heart 
Failure 
0.260 
HIV Infection 0.028 HIV Infection 0.833 
Acute Coronary Event 0.468 Acute Coronary Event 0.059 
Acute Infectious 
Event 
0.000 
Acute Infectious Event 
0.000 
Kt/V 0.410 KT/V 0.372 
Treatment Time 0.016 Treatment Time 0.663 
Ultrafiltration Rate 0.053 Ultrafiltration Rate 0.392 
 
R2 = 0.122 (Adjusted R2 = 0.092) 
 
R2 = 0.151 (Adjusted R2 = 0.127) 
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Table 9.  Results of Logistic Regression for Serum Albumin (169) 
   
Variables entered Significance (p) Odds ratio (95% CI) 
Treatment Time > 4 hours 0.012 0.488 (0.280-0.851) 
Ultrafiltration Rate 0.415 0.979 (0.929-1.031) 
Age 0.144 1.011 (0.996-1.025) 
Female Gender* 0.130 0.731 (0.487-1.097) 
Ethnicity (Caucasian)† 0.000 3.386 (1.712-6.697) 
Dialysis Vintage 0.078 0.996 (0.991-1.000) 
Diabetes Mellitus 0.073 1.466 (0.964-2.229) 
Acute Coronary Event 0.467 0.808 (0.455-1.435) 
Congestive Heart Failure 0.590 1.119 (0.743-1.684) 
HIV Infection 0.340 2.382 (0.401-14.163) 
Dry Weight 0.016 0.985 (0.972-0.997) 
KT/V 0.136 1.645 (0.855-3.166) 
Vascular Access Type‡ 0.659  
Tunneled Catheter 0.941 0.981 (0.595-1.619) 
Temporary Catheter 0.224 1.640 (0.739-3.637) 
Arteriovenous Graft 0.829 1.104 (0.448-2.721) 
Acute Coronary Event 0.096 2.082 (0.879-4.932) 
Acute Infectious Event 0.007 2.098 (1.219-3.609) 
 
Stepwise Selection for Serum Albumin 
 Variables selected 
Significance 
(p) 
Odds ratio (95% CI) 
Step 1 Treatment Time > 4 hour 0.001 0.432 (0.261-0.716) 
Step 2 Treatment Time > 4 hour 0.001 0.406 (0.243-0.678) 
  Ethnicity (Caucasian) † 0.001 2.113 (1.350-3.307) 
Step 3 Treatment Time > 4 hours 0.000 0.380 (0.225-0.641) 
  Ethnicity (Caucasian)† 0.000 2.266 (1.440-3.565) 
  Acute Infectious Event 0.002 2.322 (1.379-3.910) 
Step 4 Treatment Time > 4 hours 0.001 0.397 (0.235-0.672) 
  Ethnicity (Caucasian) † 0.000 2.304 (1.462-3.630) 
 Acute Infectious Event 0.003 2.240 (1.327-3.780) 
  Dialysis Vintage 0.041 0.995 (0.991-1.000) 
Symbols: *reference: male; †reference: African American; ‡reference: native AV 
fistula access  
Abbreviations: HIV = human immunodeficiency virus 
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Table 10.  Results of logistic regression for C-reactive protein (169) 
 
Variables entered Significance (p) Odds ratio (95% CI) 
Treatment Time > 4 hours 0.965 1.010 (0.643-1.587) 
Ultrafiltration Rate 0.333 1.022 (0.978-1.068) 
Age 0.031 1.015 (1.001-1.028) 
Gender* 0.085 0.726 (0.504-1.045) 
Ethnicity (Caucasian)† 0.045 0.519 (0.274-0.984) 
Dialysis Vintage 0.151 1.003 (0.999-1.007) 
Diabetes Mellitus 0.465 1.155 (0.785-1.701) 
Acute Coronary Event 0.926 1.025 (0.609-1.725) 
Congestive Heart Failure 0.032 1.496 (1.035-2.162) 
HIV Infection 0.697 1.379 (0.273-6.964) 
Dry Weight 0.044 1.012 (1.000-1.024) 
KT/V 0.590 1.166 (0.668-2.035) 
Vascular Access Type‡ 0.078  
Tunneled Catheter  0.059 1.589 (0.982-2.571) 
Temporary Catheter 0.044 2.053 (1.018-4.141) 
Arteriovenous Graft 0.426 1.427 (0.595-3.420) 
Acute Coronary Event 0.735 1.161 (0.490-2.749) 
Acute Infectious Event 0.091 1.601 (0.928-2.760) 
 
Stepwise Selection for C-reactive protein 
 Variables selected 
Significance 
(p) 
Odds ratio (95% CI) 
Step 1 Congestive Heart Failure 0.000 1.872 (1.341-2.613) 
Step 2 Age 0.022 1.014 (1.002-1.026) 
  Congestive Heart Failure  0.003 1.693 (1.199-2.390) 
Step 3 Age 0.020 1.014 (1.002-1.026) 
  Congestive Heart Failure  0.006 1.634 (1.154-2.312) 
  Acute Infectious Event 0.030 1.799 (1.059-3.056) 
Symbols: *reference: male; †reference: African-American; ‡reference: native AV 
fistula access 
Abbreviations: HIV = human immunodeficiency virus 
 
The Mann-Whitney test demonstrated that treatment time lasting longer than 4 hours was 
associated with having significantly higher albumin (mean rank 322.63 vs. 248.42, 
p<0.0001), whereas its effect on CRP was not significant (p=0.85).  UF rate had no 
significant effect on albumin or CRP levels (p=0.326 for albumin, p=0.931 for CRP ranks, 
respectively) (169) 
 
DOI:10.14753/SE.2018.2065
46 
 
4.3 Tunneled Dialysis Catheter removal success rate and biomarkers 
4.3.1 Results of the Inpatient Cohort 
Our Study A population consisted of 55 hospitalized patients. All TDCs were 
removed at the bedside and most cases (50/55 or 90.9%) completed by nephrology 
fellows under attending physician’s supervision. The rest of the catheters were removed 
by the attending physician alone with medical resident(s) observing the procedure. 
General cohort characteristics are shown in Table 11. (114). Most TDC removals took 
place in general wards (63.6%), while the rest of the removals were done either in the ED 
(12.7%) or one of the ICUs (23.6%) with a median time of 3 days [25-75% IQR 1-13] 
elapsing from admission with TDC in place or TDC placement. Of these, 36 (65.5%) 
TDCs were removed from the right internal jugular position, 14 (25.5%) from the left 
internal jugular position, and 5 (9.1%) from femoral veins. Most cases had urgent 
indication for TDC removal with potential for harm with delays. These included proven 
(culture-positive) bacteremia in 36.4% of the cases, otherwise unexplained fever in 41.8% 
of the cases or clinical signs of sepsis with hemodynamic instability or respiratory failure 
in 20% of the cases. Only three TDCs were removed in patients with recovering renal 
function, for the reason of being “no longer needed.” At the time of TDC removal, four 
(7.2%) patients were hypothermic, 33 (60%) were febrile or subfebrile (temperature >37 
Co) and 7 (12.7%) were on vasoactive supporting agents (norepinephrine or high dose 
dopamine). All removals were executed successfully without any retention of 
polyethylene (“Dacron”) cuffs or catheter fracture observed. One patient had prolonged 
local bleeding which was controlled with extended local pressure. None of the cases 
required interventional radiology or general surgery consultation for assistance (114). 
Peak CRP (available in 63.6% of the cohort) was 12.9 ±8.4 mg/dL (reference range: <0.49 
ml/dL), median troponin-I (34% available) was 0.127 ng/mL [25-75% IQR 0.03-0.9] 
(reference range: <0.034 ng/mL) and they did not correlate with each other (p=0.848). 
The associations of CRP and troponin-I with clinical indications for TDC removal and 
selected clinical parameters are shown in Table 12. (114).  We did not observe any 
association between CRP and clinical indications for TDC removal. Additionally, clinical 
sepsis (as indication for TDC removal) correlated with systolic BP nadir (p<0.0001), 
temperature (p=0.002) and the lowest platelet count (p=0.016).   
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Abbreviations: BP, blood pressure; CRP, C-reactive protein; WBC, white blood cell 
Obtained within 72 hoursa, 48 hoursb or 24 hoursc of the procedure.  
CRP values available for 63.6% of cohort; troponin-I for 34%. 
 
Troponin-I had no association with systolic and diastolic BP or clinical sepsis as 
indication for TDC removal. However, troponin-I, as a continuous variable showed a 
trend with confirmed bacteremia (p=0.075); furthermore, the association of troponin-I as 
a bivariate variable (abnormal/normal) with bacteremia was statistically significant 
(Pearson’s chi-square=0.456, p=0.049) [Table 2.; 3rd column] (114). 
4.3.2 Results of the Mixed Inpatient-Outpatient Cohort 
For study B, we collected data on 138 subjects, where the mean age was 50 ±15.9 years, 
49.3% being female, 88.2% African American and 41% diabetic.  General cohort 
Table 11. Baseline Cohort Characteristics and Indications for Tunneled Dialysis 
Catheter Removal (N=55) (114) 
 
Age (years) 53.9 (15.4) 
Gender (%, female) 54.5 
Race (%, African-American) 90.9 
Heart Rate (/min)c 95.6 (20.6) 
Systolic BP nadir (mmHg)c 116.5 (20.7) 
Diastolic BP nadir (mmHg)c 64.9 (12.3) 
Temperature (Co)b 37.6 (1.8) 
Blood Urea Nitrogen (mg/dL)a 46.8 (23.6) 
Creatinine (mg/dL) a 6.96 (3.37) 
Platelet count, nadir (x103/mm3)c 189.6 (114.8) 
WBC count, peak (x103/mm3)c 13.6 (8.7) 
WBC count, nadir (x103/mm3)c 7.9 (4.6) 
Hemoglobin, nadir (gm/dLc 9.4 (1.6) 
  
Biochemical Markers 
CRP (mg/dL)b  [<0.49 ml/dL]   12.9 (8.4) 
Troponin-I (ng/mL)b  [<0.034 ng/mL] 0.534 (0.708) 
 
Indication for TDC Removal 
Bacteremia  36.4 % 
Fever (temperature >38 Co) 41.8% 
Clinical Sepsis 20% 
Recovered Renal Function  5.5% 
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Abbreviations: BP, blood pressure; CRP, C-reactive protein, TDC, 
tunneled dialysis catheter; WBC, white blood cell. 
Obtained within 48 hoursb or 72 hoursa of the procedure; #considered as 
a continuous variable.  CRP values available for 63.6% of cohort; troponin-I for 34%. 
 
characteristics are shown in Table 13. The site of removal was the right internal jugular 
in 76.8% of the cases, the left internal jugular in 15.2% and one of the femoral vein in 
8%; 44.9% of the cases took place in an outpatient setting. Main indications at the time 
of removal were proven bacteremia in 30.4% of the cases, clinical septic or infected state 
in 15.2%, along with “TDC no longer necessary” in 52.2% due to either recovery of renal 
function or maturation of permanent dialysis access [Table 13.]. Most of the outpatient 
removals took place due to access maturation (p<0.0001). Like in Study A, all removal 
procedures were successful and tolerated without tear of the catheter itself but, unlike in 
study A, we observed Dacron “cuff” separation and subcutaneous retention in 6.5% of 
cases, all in males. There was a significant association between cuff retention and 
outpatient removal (p=0.007) but not with the operators’ training level, or the site of 
Table 12. Associations of C-Reactive Protein and Troponin-I with Clinical 
Indications for TDC Removal and Selected Clinical Parameters (114) 
 CRP 
(mg/dL)# 
p value 
Troponin-I 
(ng/mL)# 
p value 
Troponin-I  
(Bivariate: 
abnormal/normal) 
p value 
Indication for TDC Removal 
Bacteremia 0.806 0.075 0.049 
Fever (temperature >38 
Co)  
0.005 0.235 0.018 
Clinical Sepsis 0.977 0.446 0.659 
 
Clinical Parameters 
Systolic BP nadir 
(mmHg)c 
0.690 0.561 0.254 
Diastolic BP nadir 
(mmHg)c 
0.526 0.288 0.945 
Temperature (Co)b 0.031 0.941 0.256 
Platelet count, nadir 
(x103/mm3)c 
0.292 0.745 0.912 
WBC count, peak 
(x103/mm3)c 
0.225 0.383 0.594 
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removal. Once again, similarly to study A, none of the patients required interventional 
radiology or general surgery consultation for assistance (170). 
 
Table 13.  Baseline Cohort Characteristics (N=138) (170) 
 
Age (years) 50 (15.9) 
Gender (%, female) 49.3 
Race (%, African-American) 88.2 
 
Co-existing Medical Conditions (%) 
Diabetes Mellitus  41 
Systemic Lupus Erythematosus  6 
Hypertension 85.1 
Recent Renal Transplant 6.6 
 
Biochemical Parameters 
Blood Urea Nitrogen, highest (mg/dL)a 
(n=109) 
46.4 (18.9) 
Creatinine, highest (mg/dL)a (n=109) 7.7 (3.9) 
Platelet count, nadir (x103/mm3)a  
(108) 
223.4 (108.5) 
PT International Normalized Ratio, highesta (n=56) 1.12 (0.31) 
PTT, highest (sec)a (n=58) 33.1 (8.5) 
WBC count, peak (x103/mm3)a (n=108) 9 (4.7) 
Hemoglobin, nadir (gm/dL)a (n=108) 10.2 (1.5) 
 
aobtained within 72 hours (before or after procedure) 
 
 
 
Table 14.  Procedure Location and Indications for Tunneled Dialysis Catheter (TDC) 
Removal (N=138) (170) 
 
Location of TDC removed (%) 
Femoral vein (left or right) 8 
Right Internal Jugular Vein 76.8 
Left Internal Jugular Vein 15.2 
Place of TDC Removal (%, outpatient services) 44.9 
Indication for TDC Removal (%) 
Bacteremia  30.4 
Fever  (temperature >38 Co), Sepsis or Clinical Concerns for Infection 15.2 
Exit Site Infection (as sole indication) 1.4 
TDC “no longer needed” (renal recovery or access maturation) 52.2 
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5. Discussion 
5.1 Volume-related weight gains in critically ill patients with AKI  
Volume management is very challenging even for stable, outpatient ESRD 
patients. Critically ill ICU patients with renal impairment and hemodynamic instability 
are the most vulnerable to adverse consequences of volume overload. Early publications 
on adult cohorts have been derived from the non-AKI surgical literature, noting increased 
morbidity and mortality in volume-overloaded patients with acute respiratory distress 
syndrome (153, 154), sepsis (155), and surgical ICU patients (156, 157). Quite on the 
reverse, lesser fluid gains were associated with better outcomes after colon resection (157) 
or in the case of abdominal compartment syndrome (158, 159). Subsequent studies and 
meta-analyses further corroborated these findings (174).  Fluids are medication, not 
unlike antibiotics, glucocorticoids or blood pressure medication but an “ideal” fluid 
management in ICU settings remains insufficiently defined (175). In terms of the clinical 
significance of pre-CRRT fluid overload, pediatric literature predated material on adults, 
documenting the graded adverse impact of fluid overload in children (162, 163, 176). As 
surprisingly this may sound – pediatric cohorts are always smaller than adult ones – 
children are nonetheless less likely to be confounded by multiple comorbidities of aging 
and may demonstrate biomedical signals with less ambiguity. To state it differently, both 
surgical and pediatric cohorts with fluid overload may have represented a relatively “pure 
model” fluid overload in critical illnesses, leading to an earlier recognition of the 
phenomenon. Among adults, however, our group(167) was one of the first to describe the 
progressive risk of death with increasing fluid overload in critically ill renal-failure 
patients, as discussed earlier in the Results section of the present thesis. Our central 
finding was that patients with VRWG ≥10% had a markedly higher mortality than those 
who gained <10% (63% vs. 39%), despite being reasonably similar with regard to 
demographics, severity of illness, sepsis or oliguria (167). Fluid (volume) overload may 
dilute the serum creatinine and result in a delay of recognizing AKI and the initiation of 
appropriate work-up and therapy for it (131-133). In keeping with such speculations, we 
detected lower creatinine with larger VRWG. We speculate that VRWG and fluid 
overload were, to a large degree, a surrogate for hypotension, labile hemodynamics or 
capillary leak, and overall severity of illness in our cohort. The kidneys are encapsulated 
organs, where a large degree of volume overload, especially in septic patients with 
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capillary leak may lead to compromised renal perfusion (177, 178). All our patients 
commenced on CRRT subsequently, further testifying to the severity of the illness of the 
cohort (166). The predominant local practice of the day of administering large amounts 
of IV fluids - rather than early vasoactive pressor administration - may have created some 
of the very large VRWG and may not be uniformly observed in all centers all over the 
word. If, however, the VRWG was simply a severity of the disease marker, one would 
have expected the impact on mortality to be diminished when adjusted for the severity of 
illness (e.g. Apache scores). Our multivariate analysis (which contained Apache II scores, 
diagnosis of sepsis, oliguria and VRWG) did not support this possibility, although 
“generic” illness severity scoring systems are known to have a relatively poor 
performance in similar cohorts (151, 179).  Preceding our publication, findings from the 
Sepsis Occurrence in Acutely ill Patients multi-center database (165), observed larger 
fluid gains in non-survivors of AKI. The Program to Improve Care in Acute Renal 
Disease (PICARD) group (180) analyzed data from critically ill adult patients with AKI 
from multiple ICUs in the U.S. The same group of authors in 2009 observed the 
association of fluid overload with mortality, irrespective of the modality of RRT(181). 
Our 2010 study was the first to focus specifically on the impact of VRWG before CRRT  
in adult cohorts (167).  
Oliguria is generally associated with worse outcomes in patients with AKI (151, 
165, 182), which is in accordance with our findings as well; mortality was 60.4% in 
oliguric subjects compared to 39.8% in non-oliguric subjects. Oliguria was not defined 
based on weight (mL/kg/hour) and our definition of oliguria deviated from the current 
definition of the AKIN. Our study had several additional limitations evident even at the 
time of publication: lack of knowledge about weight changes before admission and the 
uncertainty about baseline creatinine in about one-fourth of the subjects. Additional 
methodological limitations (modest size, single-center design and lack of randomization) 
would have made our findings difficult to support without other studies reaching the same 
conclusion. Delays and individual practice patterns in obtaining renal consults may have 
influenced the timing of CRRT initiation, further questioning the external validity of our 
findings. Nevertheless, the subsequent years from 2010 on produced a flurry of supportive 
investigations on the subject as noted below.  
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5.1.1 Literature on the importance of volume overload in critically ill patients with AKI  
Subsequent to our publication, Heung et al. documented that among patients 
surviving AKI, fluid overload at the beginning of RRT was associated with compromised 
renal recovery after recovery from critical illnesses (183).  Pediatric studies continue to 
support the importance of VRWG even in very small-sized children (184).  Most 
importantly, a number of other investigations of adult cohorts replicated our findings on 
the importance of VRWG in AKI.  These include a Finnish trial of ICU patients, 
demonstrating higher 90-day mortality risk after adjusting for disease severity, RRT and 
sepsis (185); an Italian multicenter trial demonstrating that both fluid overload and 
oliguria were independent risk factors for 28-day mortality after adjustment for age, sex, 
diabetes, hypertension, diuretic use, non-renal Sequential Organ Failure Assessment 
(SOFA)  and sepsis (186) (adjusted hazard ratio [aHR] 1.67 per L/day, 95% CI 1.33-2.09 
for fluid overload, p<0.001); and aHR 0.47 per L/day per L of urine output, 95% CI 0.33-
0.67 for oliguria, p<0.001 for both). On the other hand, diuretics use was associated with 
better survival in this population (aHR 0.25, 95% CI 0.12-0.52; p<0.001). In 2015 a very 
large, multicenter trial from Beijing, China once again confirmed that volume overload 
was an independent risk factor for new-onset AKI with OR 4.508 (95% CI 2.900-7.008; 
p<0.001) and increased the severity of AKI (187). Additionally, non-survivors with AKI 
had higher cumulative fluid balance during the first 3 days than survivors (2.77 [0.86-
5.01] L versus 0.93 [−0.80 to 2.93] L; p<0.001). Multivariate analysis revealed that the 
cumulative fluid balance during the first 3 days was an independent risk factor for 28-day 
mortality (187).  Most recently, the Dose Response Multicentre Investigation on Fluid 
Assessment (DoReMIFA) study demonstrated that volume overload was more harmful 
in the presence of AKI and preceded renal dysfunction. Both the severity and rapidity of 
fluid accumulation development were independent risk factors for ICU-associated 
mortality (188). A systematic review and meta-analysis also confirmed the associations 
between fluid overload and mortality in AKI patients but found only a non-significant 
trend for the association of fluid overload with renal recovery (189). Notwithstanding the 
limitations - as summed up in our review paper -   “…these observations, however, have one 
major potential major error – confounding by indication, i.e., sicker patients were more likely to 
be hypotensive and received larger amount of fluids in an attempt to control hypotensive 
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tendency”(135),  sufficient replications of our study findings in multiple settings provide 
external validity to support our initial findings.  
5.1.2 Fluid composition and AKI 
Attempts at modifying intravenous fluid composition used for volume 
resuscitation have not been successful so far. Literature emerging over the last decade 
attempted to support the use of colloid solutions over crystalloid solutions for volume 
resuscitation; however, concerns emerged about the association between hydroxyethyl 
starch and increased propensity for AKI in patients with sepsis (145). Similarly, albumin 
use failed to confer any survival benefits in controlled clinical trials (142, 143) and may 
have contributed to increased intracranial pressure in select individuals with brain trauma. 
Preventing metabolic acidosis with bicarbonate-enriched solutions may have an 
advantage over uncorrected metabolic acidosis (149, 175). In summary, it appears that 
the degree of net fluid gained (VRWG) is a stronger predictor of outcomes than the type 
of fluid administered during the early phase of treatment after admission.  
5.1.3 Renal replacement therapy choices – intermittent vs continuous  
The choice between intermittent vs continues RRT remains a difficult one and 
published literature to date has not demonstrated the superiority of CRRT (190). 
Similarly, the recent (2012) reiteration of Surviving Sepsis Campaign did not specifically 
endorse CRRT over intermittent HD (191). The debate about this clinical conundrum 
continues among nephrologists, as summarized in our recent review:  
“To address hypotension and volume overload in anuric subjects, CRRT is often preferred to 
intermittent hemodialysis to better control VRWG (190). Historically, the better tolerance of 
CRRT vs. conventional intermittent HD was attributed exclusively to the prolonged nature of 
the former enabling more fluid removal over an extended time period (192, 193). Nonetheless, 
at least clinical experience suggests that the true merit of RRT is not its ability to remove large 
amounts of fluid but in doing so while provoking less hemodynamic instability. Several 
mechanisms may contribute to decrease of hypotensive tendency during CRRT (in particular, 
during veno-venous hemofiltration) to afford net fluid removal (194). Early modalities of 
continuous therapies without built-in heater circuit likely provoked cooling with subsequent 
shivering and vasoconstriction, contributing to the improved BP on CRRT. Certainly, in this 
writer’s clinical experience, it appears that the ability of CRRT to decrease hemodynamic 
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instability is the primary process by which may improve outcomes. With successful source 
control, such as removing the source of infectious-inflammatory injury (e.g., abscess drained), 
we have observed many times gradual improvement of BP after 4-6 hours, enabling the 
clinicians to start net fluid removal. Nonetheless, individual responses are tremendous and calls 
for astute clinical re-evaluations in these patients. With regard to expected tolerated fluid 
removal, it appears the most obvious rule appears to be the lack of such.  Accordingly, there is 
no apparent replacement for an astute clinician’s daily assessment and judgement to estimate 
expected tolerance of fluid removal.”(135)  
Time of initiation (195, 196), modality (193, 197), dose (198, 199), intensity and duration 
of CRRT (197, 200, 201), all of these remain argued in the literature without a clear 
preference of one over the other. Nonetheless, securing patency of the CRRT circuit 
remains a critical challenge in the ICU and multiple modalities, including regular heparin 
anticoagulation, regional citrate anticoagulation or the combination of both may fail in 
select patients to maintain circuit patency (202, 203). Our standard protocol of regional 
citrate anticoagulation at the University of Mississippi resulted in an overall mean filter 
life of ~45 hours and approximately 70% patency rate at 72 hours (unpublished 
observation of the author of this thesis).  
5.1.4 Assessment of volume overload  
Multiple technologies are emerging to assist clinicians in this setting, including 
the assessment of inferior vena cava size, bioimpedance (6, 38, 204), the assessment of 
lung water content by ultrasound (205, 206) and biochemical markers for volume 
overload, such as elevated brain-type natriuretic peptide (BNP) (38, 207, 208).  With 
regard to B-type natriuretic peptides, pro-atrial natriuretic peptid, BNP and N-terminal-
pro-BNP all correlate independently with age, degree of systolic dysfunction and 
negatively with residual diuresis and 2-year survival, as well (209). Discordant results 
between BIA and BNP can be explained by capillary leaks during septic shock (210). 
Limited investigations explored the use of BIA-based vector analysis in assessing the 
degree of volume overload in ICU patients and potential associations with subsequent 
outcomes (208). On the other hand, multi-channel, total-body bioimpedance 
examinations remain severely underutilized and unexplored in critically ill, volume-
overloaded ICU patients with AKI (135).  
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5.1.5 Potential role of peritoneal dialysis in volume overloaded subjects 
One of the enigmas of clinical nephrology is the relatively good success rate of 
acute peritoneal dialysis (PD), practiced in resource-limited environments, comparing 
favorably to a much more resource-expensive technology, the slow continuous 
hemodialysis or hemodiafiltration (211-216).  Acute abdominal compartment syndrome 
is an expected complication of over-aggressive volume resuscitation (174).  Most 
importantly, as we pointed out in our recent review paper (135), the use of a temporary 
acute PD catheter virtually eliminates the possibility of abdominal compartment 
syndrome in severely volume-overloaded and critically ill medical ICU patients with 
acute ascites. In these subjects, the clinical success may be partially disconnected from 
the “clearance” provided by the acute PD and linked to improved perfusion of visceral 
organs in volume-overloaded subjects with acute ascites.  
5.1.6 Alternatives to serum creatinine to assess renal function; biomarkers in AKI?   
The Translational Research Investigating Biomarker Endpoints in AKI (TRIBE-
AKI) Consortium has prospectively examined serial biomarker profiles in 1219 adults 
and 311 children scheduled for cardiac surgery in nine centers. They found that cystatin-
C was superior to serum creatinine and serum creatinine-derived eGFR to predict AKI 
(217). An alternative strategy is to consider volume overload-adjusted changes in serum 
creatinine. To control for volume overload driven decrease of serum creatinine, literature 
has been published to predict the value of volume overload-corrected baseline serum 
creatinine (132, 133):  corrected Cr= baseline Cr x correction factor [Correction factor = 
baseline water space + accumulated fluid balance/ baseline water space (baseline water 
space: weight (kg) x 0.6)]. However, the practical value of the formula to improve 
survival predictions is not yet fully defined and understood. Our own results from the ICU 
cohort of us(167) certainly suggest that dilution of creatinine may have contributed to 
weakening of the effect of VRWG, but we have not specifically analyzed the data for this 
possibility. On the other hand, the literature on “biomarkers” of AKI is vast and ever-
expanding (218). Our overall concerns with the existing approaches are summarized in 
our recent review paper, as well:  
“Despite more than a decade of unfulfilled promises and spent efforts, we are yet to see a true 
disruptive technology to replace conventional markers or a seasoned clinicians’ experience.  
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Taking a prime example, newer biomarkers of AKI are yet to supersede a very imperfect but 
much simpler biochemical marker, the serum creatinine in clinical utility (219). The added costs 
of newer biomarkers for AKI are an additional concern, especially in resource-limited settings. 
The heterogeneity of clinical etiology for AKI is yet another challenge for biomarker-based 
diagnostic procedures. In many instances, the underlying etiology of AKI is unclear; in contrast, 
many biomarker-defined prognostic schemes have been derived from a specific disease cohort 
of patients. Only few studies used dedicated study adjudicators in attempt to develop rigorous, 
consensus-based clinical definitions to correlate the markers.  Complexity is another problem. 
In a time-pressured busy environment any recommended prediction model has to be either very 
simple or it needs to be easily available via the healthcare system computer and bioinformatics 
network. There is also a major internal limitation for renal biomarkers.  While most of the 
biomarker studies are focused on kidney-derived enzymes or products, AKI is in fact a systemic 
illness in many instances, being only one feature of multiple organ failure syndrome. 
Accordingly, there is a major conceptual difference between the so called “renal angina” (220, 
221) and, for instance, the classic paradigm of myocardial infarction (MI). In MI, the prime 
cause of abnormality is the necrosis of myocardial tissues; in renal diseases, most commonly, 
AKI is a functional consequence of a systemic process.” (135)  
To further support this viewpoint, in a recent series of limited autopsies by Takasu et al., 
only a limited degree of renal injury was detected in the examined tissues, markedly 
disconnected from the profound functional impairment taking place before death (222). 
5.1.7 Oliguria   
In most clinical contexts, decreases in the urine output (oliguria) implies an acute 
hemodynamic process or an acute component of renal failure. Oliguria is an excellent 
independent risk factor predicting adverse renal outcomes (186, 223, 224) as it may be a 
sign of an overall clinical illness, such as an emerging sepsis. Accurate hourly urine output 
is difficult to obtain but can add to the assessment of these patients (225). Urine output, 
however, is not the same as creatinine excretion; only hourly monitoring of creatinine 
excretion would offer a fair chance of “real-time” monitoring of GFR. A major concern 
about using oliguria as an independent clinical parameter is, according to the author of 
the present thesis, the lack of adjustment for volume status. Often, fluid is given without 
a clear assessment of the underlying disease processes or the volume overload already 
taking place. Excessive volume resuscitation may be counterproductive in tissue hypoxia 
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with massive volume overload and in those with pulmonary edema and respiratory failure. 
As we pointed out in our very recent review:  
“…the presence of low urine output cannot have the same meaning in an approximately 
euvolemic subject as opposed to one already markedly volume overloaded (>10 or 20% 
VRWG). In doing so, the scenario would be somewhat analogous for patients on mechanical 
ventilator support… [to] interpret an arterial blood gas panel and oxygenation without knowing 
the partial pressure or percent of O2 on the inhaled gas.” (135). And “…before being lost in the 
plethora of various biomarkers or a myriad of derived hemodynamic parameters, clinical 
nephrologist should consider using and correctly interpreting basic parameters of critically ill 
patients with renal failure in ICU. Similar to urine output, VRWG should be considered as “renal 
vital sign,” incorporated into the rounding report and daily consideration of care decisions.” 
(135).  
Indexing the urine output for the degree of volume overload is a completely unexplored 
area of biomedical research and another low-cost technology to potentially assess disease 
severity (135).  
 
5.2 Time on hemodialysis 
To our knowledge, our publication (169) demonstrated for the first time a positive 
association between treatment time and albumin levels in chronic hemodialysis patients, 
with a significantly decreased risk (OR 0.397, 95% CI: 0.235-0.672; p<0.001) of 
hypoalbuminemia (<40 gm/L) in those dialyzing longer than 4 hours. Unlike time on 
dialysis, small solute clearance (Kt/V) was not associated with better albumin values in 
our study. Past studies of better survival with higher albumin levels (226) may have 
reflected a better-dialyzed state of patients due to longer treatments, better preserved RRF 
(227) or both.  Longer treatment times achieve a better clearance of larger middle-
molecular size substances (79) at a price of lesser hemodynamic fluctuations (228, 229). 
Volume removal and ultrafiltration rate are, nevertheless, closely integrated features with 
dialysis duration. Longer treatment time allows for slower fluid removal over a more 
prolonged period and thus, avoids repetitive episodes of intradialytic hypotension (228, 
230), decreases hemodynamic fluctuations (228, 229) and may contribute to preservation 
of RRF (227).  Low albumin is a risk factor for early readmission after hospital discharge 
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among the elderly (231). As most putative uremic toxins diffuse more slowly than urea 
(232), their removal will be largely a function of time spent on dialysis. Beside the longer 
treatment time, we also recorded lower UF rates and longer treatment than reported by 
the DOPPS from the US at that time (168). 
Contrary to our expectations, unlike albumin, CRP showed no significant 
association with treatment time in our network. Nonetheless, our statistical model 
explained a remarkably little variation of CRP levels (R2 = 0.127) while several factors 
thought to influence CRP in a similar population without end-stage renal disease (233) 
did not appear significant in our cohort.  While a statistically significant association has 
been observed between CRP and the choice of catheter for vascular access (p=0.002), this 
was not maintained during stepwise regression. Although the hemodialysis procedure 
itself is known to potentially increase acute phase reactants levels (234, 235), more 
prolonger treatments may result in better clearance of larger middle-molecular size 
substances (79). With regard to congestive cardiomyopathy (OR 1.634, 95% CI: 1.154-
2.312; p=0.006), there have been reports documenting the association of congestive 
cardiomyopathy and CRP in non-renal patients (236, 237) and between CRP and volume 
overloaded state in both pre-dialysis (238) and peritoneal dialysis patients (239).  Our 
study extended this potential association to the hemodialysis population.  Anti-
hypertensive agent class is known to exert some modest influence on CRP in hypertensive 
sibships (233), although such relationship is not well explored in ESRD. 
In our study, the UF rate did not correlate with either inflammatory marker, which 
was not what we have expected.  Possible explanations for the phenomenon are either a 
true lack of influence or a balance of competing influences. As most dialysis sessions last 
very close to the same duration (four hours), the UF rate will become largely a function 
of IDWG determined by appetite.  Healthier patients may be less compliant with salt and 
water restrictions to accommodate an intact appetite.  Accordingly, we speculated that 
some of the potential long-term harmful effects of increased UFR may be 
counterbalanced by a better appetite in healthier patients. (169) We also have observed 
remarkable similar biochemical outcomes (albumin, CRP) between the US and Hungarian 
arm of the cohort. We believe this observation demonstrates that good outcomes can be 
reached in disadvantaged and minority populations with attentive medical and dialysis 
care. (169)   
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5.2.1 Recent literature of treatment time, survival and BP control 
Among DOPPS participants between 1996 to 2008, dialysis treatment time 
increases by 30 minutes was associated with a proportionate decline of all-cause mortality 
of 6% (130). Further, longer treatment times were associated with higher hemoglobin and 
albumin and lower WBC count and phosphorus concentrations (130). Shorter dialysis 
time (session length <240) was also shown to be associated with increased mortality in a 
large database of Fresenius Medical Care North America (aHR: 1.32, 95% CI: 1.03-1.69) 
(240). In a post hoc analysis of the 150 participants in the Dry-Weight Reduction in 
Hypertensive Hemodialysis Patients trial (N=150), fewer hours of dialysis treatment was 
associated with higher systolic BP, increased need for BP medications and a longer time 
to achieve a lower BP target (241). Similarly to past studies, in a subsequent study we 
demonstrated that post-dialytic (post-ultrafiltration) BPs had a better association with 48-
hour BP burden during ABPM than predialysis BP (30). Additionally, we also 
demonstrated that by incorporating both pre- and post-dialysis BP values into linear 
regression modeling, pre-dialysis systolic BP readings lost significance entirely to predict 
ABPM-derived systolic BP (30). With the usual practice of three-times-a-week renal 
dialysis, BP variability is at the peak on the first dialysis of the week, when excess volume 
is likely to be the largest (126). Further, elevated systolic BP variability (defined as SBP 
variability above the medium) was associated with increased all-cause mortality (HR 
1.51, 95% CI: 1.30-1.76; p<0.001) and cardiovascular mortality (HR 1.32, 95% CI, 1.01-
1.71; p=0.04)  in a cohort of 6393 prevalent adult HD patients (124). Paradoxical 
increases of blood pressure during treatments are associated with poor subjective 
symptoms and are indicative of increased future hospitalization rates, adverse 
cardiovascular outcomes and a rise of all-cause mortality (242, 243). The lowering of 
dialysis temperature may be poorly tolerated by patients, but leads to vasoconstriction 
and a relative rise of BP. Lowered counter-current temperature is associated with 
improved hemodynamic stability (244) and reduced white matter lesions in the brain 
(245). Clinical assessment can be incorrect in about 25-40% of patients to identify 
euvolemia correctly, at least in terms of overall body salt-water content (246). BIA-based 
assessment leads to less fluid overload (58) and improved left ventricular hypertrophy 
(53); further, prospective BIA-monitored EDW adjustments may be associated with 
decreased mortality in ESRD (58), though contrary evidence exists as well. 
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5.2.2 Recent literature on interdialytic weight gain 
Greater IDWG has been linked to increased adverse outcomes in multiple studies 
since (46, 240, 247). In a study by Kalenter-Zadeh et al. in an analysis adjusted for 
demographics and markers of inflammation, a graded relationship was observed with 
IDWG: increased risk of CV death for ≥4 kg (aHR 1.25, 95% CI: 1.12-1.39) and 
decreased risk for <1 kg (aHR 0.67, 95% CI: 0.58-0.76), when compared to the reference 
group of 1.5-2 kg (46). A study by Flythe et al., from a cohort of over 14,000 prevalent 
HD patients, noted a 29% increase of mortality risk associated with higher (>3 kg) IDWG 
relative to lower (≤3 kg) IDWG (240). At the same time, the authors also demonstrated 
that session length of < 240 minutes had a similar negative impact on survival (aHR 1.32, 
95% CI: 1.03-1.69). And, finally, a chronically volume-expanded state with missing 
EDW by >2 kg and >30% of the time was also associated with adverse CV and all-cause 
mortality (aHR 1.28, 95% CI: 1.15-1.43) (40). Similarly to the above, Cabrera et al., 
observed a stronger impact in terms of the relative change of weight; specifically, relative 
weight gain of >3.5% body weight was independently associated with multiple CV 
outcomes (CV mortality, myocardial infarction and heart failure) (248).  Among other 
parameters, shorter treatment times with higher hourly UF rates may impact sudden 
cardiac death rates adversely (249). Some of the published literature debate the 
independent value of UF rate or volume when adjusting for the presence of volume-
overloaded state at the beginning of renal dialysis (60). Dialysate sodium itself exerts an 
influence on both IDWG and BP control in ESRD. The most recent DOPPS data between 
phases 2 and 5 (2002 - 2014) indicated a modest decline of IDWG world-wide, probably 
mediated by a trend to use lower sodium concentrations and the avoidance of sodium-
profiling during RRTs (250). For each 1 mEq/L rise of the dialysate sodium concentration, 
there was an associated rise of 0.13 kg (95% CI: 0.11-0.16) of IDWG. Among the 
participating regions, drops in IDWG were most evident in North America and Europe. 
Once again, mortality rate was higher for relative IDWG > 5.7% (aHR: 1.23; 95% CI: 
1.08-1.40) compared to the reference category of 2.5 - 3.99% weigh gain (250).  
5.2.3 Dialysis nonadherence 
Historically, restrictions on sodium and water have been advocated to curb IDWG. 
They are, however, conceptually not equivalent. A weight gain of free water would be 
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distributed through the entire water space (albeit at the price of decreasing serum sodium); 
on the other hand, the intake of salt would stimulate thirst and make the drive of fluid 
intake very hard to avoid (251). The resultant expansion would be effectively limited to 
the extracellular water space. All dialysis units should carefully consider the local cultural 
microenvironment to identify causes and patterns of nonadherence and barriers of 
effective healthcare delivery. Recent data from the Fresenius North America database 
(2005-2009) detected higher rates of treatment nonadherence among young and non-
white subjects, with transportation issues, poor weather conditions, holidays, and non-
renal illnesses identified as the underlying reasons (252). Missed treatments were 
associated with increased risk of ED visits, hospitalization and ICU admissions (252). In 
another study, non-white patients race and larger dialysis unit size was associated with 
increased nonadherence (missed and shortened treatments) and further confirmed large 
geographic variations across the US (253). Race and trust in the health care system may 
be an additional confounding factor impacting compliance (47, 119). In the U.S., African 
Americans known to have disproportionate trust towards providers from the same ethnic 
and cultural background, including physicians  (254-256). Urban centers serving minority 
populations are known to miss various performance targets in general and have higher-
than-expected mortality rates (257). As mentioned earlier, our own experiences from the 
Southeast US documented also remarkable nonadherence: in one cohort from Northern 
Louisiana 85.9% of patients shortened at least one HD session, and 29% did not attend at 
least one HD session per month (123). Quality improvement data from the UMMC 
Jackson Medical Mall Dialysis Unit (>85% of the patients were African American) have 
shown a similar magnitude of appointment nonadherence: 78.5% of the patients shortened 
treatment by at least 10 minutes and 31.2% missed at least one HD treatment during the 
index month (personal communication from Melissa Hubbard, R.D., UMMC Nephrology 
Unit; October 2009). This latter unit is in the center of the city of Jackson, Mississippi, 
and is well served by the public transportation system. One very little studied concept is 
the potential impact of overall climatic conditions on IDWG. The impact of sweating 
itself is likely to be minimal on IDWG and, in temperate climate at least, environmental 
conditions presumed not meaningfully impact the net result of session-session variations 
of fluid intake, sweating and residual urine output (24). Sweat has a relatively little 
sodium content in healthy subjects, when compared to other body fluids (258). On the 
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other hand, in a relatively small (N=100) cohort of Hungarian patients we have shown 
that hot-dry climatic condition resulted in the least weight gain, a difference which was 
statistically significant, when compared to warm-dry conditions (24). 
5.2.4 Shortcomings of Kt/V based dialysis clearance 
Body surface area-based adjustment may be a more reliable expression of dialysis 
dosing than   the classical approach which utilizes total body water (5). Examining a 
prevalent cohort of 7229 patients undergoing thrice-weekly hemodialysis Ramirez and 
coworkers (5) found that there was no associated survival benefit associated with a single-
pool Kt/V >1.7, but the hazard ratio for mortality was progressively lower with higher 
Kt/Vs if the Kt/V was normalized for the body surface area. Thus, body surface area-
based dialysis dose results in dose-mortality relationships are substantially different from 
those with volume-based dosing. This observation may be particularly relevant to women, 
who received proportionally smaller dialysis doses, when BSA was considered. 
5.2.5 Overnight modalities – the future? 
In the future, expanding options of overnight dialysis may well address the time 
constraints of conventional dialysis and potential shortage of care staff. In one study 
obtained from the Fresenius North America database, comparing subjects with 
propensity-matched controls, overnight dialysis resulted in better clearances, improved 
control of biochemical parameters and an approximately one-fourth reduction of death 
for over a two-year period (HR 0.75, 95% CI: 0.61-0.91;  p <0.004) (259). Enrollee 
retention was a major issue: in the latter study, after 2 years only 42% of the patients were 
adherent to the modality. Additionally, further investigation of the Frequent Hemodialysis 
Network Nocturnal Trial participants showed a yet unexplored paradoxical increase of 
mortality during the post-trial follow-up period (3.7 years): 3.88 (95% CI, 1.27-11.79; 
p=0.01) (260). Our own anecdotal experience with the University of Mississippi 
Nocturnal Shift (n=9) demonstrated good biochemical and BP control, along with 
excellent Kt/V values for this small cohort of very large or multiple co-morbid chronically 
ill subjects (unpublished observation of the author of the present thesis). 
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5.2.6 The paradigm of pregnancy  
Pregnancy perhaps represents the ultimate model to define what the difference is between 
“minimum necessary” and an “optimal” dose of renal dialysis. It has been a time-honored 
observation by now that pregnant patients need more frequent or much longer sessions of 
renal dialysis, ultimately translating into a longer weekly total time on dialysis. Unlike in 
the past, when fetal survival was very rare, the more recent era is witnessing a marked 
improvement in successful pregnancy rate. One recent study has compared pregnancy 
success rates between the US and Canada, with a notable difference between practice 
patterns between the two countries. While in the US, the usual practice pattern dictated a 
daily dialysis of about 4 hours 6 days a week after the first trimester, in Canada, 
practitioners prescribe HD for 6-8 hours, 6-7 days per week as soon as pregnancy is 
recognized in a dialysis patients. This registry-based comparison observed a much higher 
successful live birth rate in Canada relative to that of the United States (86.4% vs 61.4%; 
p=0.03) (261). Further review of the Canadian nocturnal program also suggests a graded 
dose-relationship between weekly hours of hemodialysis with live births, improving from 
48% in women receiving <20 hours of therapy to 85% in those receiving ≥37 hours (261). 
Intensified therapy also decreased the number and severity of neonatal and maternal 
complications (261). 
 
5.3 Transitioning between acute and chronic renal replacement therapy: the 
importance of access choice 
In our series entailing both inpatients (114, 170) and outpatients (170, 171), we 
have documented an excellent safety profile for bedside TDC removals, presumably 
contributing to the timely care of these patients. Vascular access catheter utilization 
remains a profound and escalating problem in the U.S., with >80% patients with no pre-
ESRD nephrology care starting RRT with these devices (144), including those seeing a 
nephrologist in the preceding year (~40%). This situation has visibly worsened since the 
mid-nineties, when less than 20% of new hemodialysis patients utilized TDCs 60 days 
after the initiation of renal dialysis (262).  It is ironic that the well-intentioned mandate of 
“Fistula First” initiative led to an escalated utilization of vascular access catheters (263) 
and replaced AV grafts with a much more morbid technology of TDCs, bringing about 
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the attendant risk of infection and death (99, 106, 114, 264) Access type (non-AV fistula) 
and elevated CRP are both risk factors for future infection and both are independently 
associated with increased infection-related hospitalization, along with other markers of 
fragility (old age >85, nursing home residence, poor mobility and chronic medical 
illnesses) (265). The lack of adequate pre-dialysis nephrology care is associated both with 
higher catheter utilization and mortality within one year after the start of dialysis, 
observed both in Canada (266) and the US (267).  Long-term vascular access catheter use 
is associated with increased mortality (99, 101, 102) and every attempt should be made 
to minimize the duration of catheter-dependence.  Alternative options to avoid temporary 
access should be considered, including acute start peritoneal dialysis (268, 269) or the 
initiation of deferred hemodialysis until chronic AV access have matured.  
5.3.1 Peritoneal dialysis 
Alternatively, peritoneal dialysis (PD) remains a viable option for effective renal 
replacement therapy and alleviate the need for indwelling vascular access catheters. PD 
remains a somewhat enigmatic modality which works clinically well despite the limited 
small solute clearance it provides.  PD is cost-effective (23), avoids the need for 
temporary vascular access placement and may in fact have a survival advantage over 
hemodialysis (270), especially during first two or three years of RRT (271). Historically, 
the “slow but steady” nature of PD has been cited most often as the reason for its clinical 
efficacy. However, uremic toxins are generated disproportionally in various body 
compartments. While some tissues (muscles) are more active than others (fat tissue) to 
generate uremic toxins, in effect the largest generating compartment is the interface of 
human-bacteria in the gastrointestinal tract. In this regard, it would be perhaps most 
appropriate to view PD as a “compartment dialysis” (272), a modality delivering a 
disproportionately large clearance to the gastrointestinal tract, the very compartment 
generating most uremic toxins.  It can be offered upon transition from renal 
transplantation to maintenance dialysis, a particularly vulnerable period to excess 
mortality (273).  Survival advantages are also likely linked with the better preservation of 
residual renal function, improved hemodynamic stability, decreased need for human 
recombinant erythropoietin administration and a lesser risk of acquiring blood borne 
infections in PD (274-278). Nonetheless, with the exception of Hong Kong and Australia, 
PD remains severely underutilized all over the world.  Obesity, commonly perceived as a 
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relative contraindication to PD is by itself not a limiting issue and most studies have 
reported a survival advantage of doing PD in obese patients (274, 279-281). Further, a 
recent systemic review and meta-analysis of more than 150,000 subjects also confirmed 
at least a neutrality of large body mass index (BMI) on survival (282). Fat tissue does not 
participate in urea distribution volume (water space) and relatively inert in terms of 
production of uremic toxins.  Obesity and high BMI, however, do not always equal an 
excess of total body water space and therefore the feasibility of PD in large subjects 
without excess fat tissue is a different issue. In a single-center small cohort, we have 
documented relative success of PD in large subjects weighing >100 kg (Kt/V: 1.96 ± 0.29 
vs. 2.22 ± 0.47 in those weighing ≤75 kg) (283).  
5.3.2 Impact of access choice on morbidity and mortality  
Access-related infection is the single largest reason for admission in ESRD 
patients and a major cause of or contributor to mortality. The impact of access-related 
infection is probably under-appreciated in hemodialysis patients for the single reason that 
the definition is hinging on obtaining blood culture and clinical astuteness to seek 
infection in the background of confusing clinical presentations. It is critical to recognize 
infected TDCs and blood cultures should be obtained at a low clinical threshold of 
suspicion, preferably during dialysis (284, 285). This is highly important as uremia even 
under treatment and without blood stream access devices confirms an increased risk of 
bacteremia and fungemia (286). Our inpatient cohort was relatively ill with generally high 
CRP values.  Herewith, the measurement of CRP was unlikely to contribute further to the 
clinical decision-making. 
5.3.3 Timely removal of vascular access devices   
An inordinate amount of clinical presentations may be ultimately attributed to 
access-related infections and patients with indwelling vascular access are at a particulate 
risk (287). S. aureus is a particularly common pathogen (288). Biofilms on the catheter 
may represent a sanctuary shielding bacteremia from the therapeutic level of antibiotics, 
making eradication difficult (103). An emerging treatment trend to address the issue of 
biofilm is the intraluminal antibiotic-enriched catheter “lock” solution which, in addition 
to systemic antibiosis (289), is cutting the need for catheter removals and recurrent 
bacteremia in half (289).  Whether this strategy results in selecting out resistant bacteria 
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remains debated (289, 290). While some advocate guidewire-assisted catheter exchange 
(rather than utilizing a new puncture site), such approach is inevitably challenged by a 
higher rate of recurrence of infection. Low albumin, anemia or elevated CRP are known 
risk factors associated with adverse outcomes during TDC exchange (291, 292).  As we 
summarized in our review paper on TDC removals:  
“In our opinion, removal of TDC in the setting of endovascular infection and critical illness is 
an emergency and mandates immediate action (114, 293).  Unlike renal dialysis catheter 
placement, it is not meaningful to entertain “simulation” training for TDC removal, in lieu of 
real-life, hands-on experience at bedside (294). Furthermore, unless a clear alternative source 
(e.g., pneumonia, infected decubitus ulcer) is present on presentation, it may be prudent to 
remove TDCs empirically in hemodynamically unstable patients, while awaiting the blood 
culture results (114).”(172) … and: “Many of these patients presents with relatively non-
specific or perplexing symptoms (e.g., chest pains, shortness of breath or only mild fever) (114, 
273) and infection of TDC should be disproportionally high on the differential. Forming the 
appropriate clinical decision to remove the infected hardware is important part of clinical 
training. In addition to elevated white blood cell count, otherwise poorly explained rise of 
troponin-I (114) or CRP (169, 295) may provide useful clues early into the evaluation 
process.”(172) 
5.3.4 Complications during Tunneled Dialysis Catheter removal 
Bleedings, including major local bleedings do not appear to be a major concern 
during TDC removals. In a very recent paper by Dossabhoy et al., aspirin or clopidogrel 
therapy in roughly two-third of the cohort did not seem to increase bleeding risk (1/49 or 
2% of the subjects with minor bleeding on these medications) (171). Another study 
conducted by Martinez et al. also found that anti-platelet therapy or anticoagulation was 
not associated with an increased risk of bleeding either (296).  Checking of coagulation 
profile such as prothrombin time international normalized ratio (INR) can be generally 
reserved for patients on vitamin-K antagonist therapy or for those overtly ill and assumed 
to have consumptive coagulopathy. Only anecdotal experience exists with prolonged INR 
up until 3 (170, 171) and most of us would favor normalizing INR before catheter 
removal. Failed removal was generally rare in our experience; e.g., in the personal 
practice of the author of the present thesis (>400 removal over 15 years) this has happened 
in less than 1% of the cases. Based on our publications, it is probably expected to occur 
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no more than 1/50 – 1/200 (172). During graduate medical education training, hands-on 
assistance was needed from our faculty at a rate 6-10/100 (personal communications from 
Neville Dossabhoy, M.D., Shreveport, LA and Mihály Tapolyai, M.D., Budapest, 
Hungary). In our experience, it took approximately 5-8 supervised procedures for our 
first-year renal trainees to master the ”learning curve” for the procedure and assimilate 
the skill to competency (172). In our own series, including the one by Dossabhoy et al., 
we have not encountered catheter body tears. On the other hand, single-lumen twin 
dialysis catheters (i.e., Tesio, MedComp) are reported to fracture very easily and are not 
suitable for traction removal (297, 298).  Published literature has stated that immediate 
clamp compression of the proximal catheter fragment is to be executed to prevent air 
embolism or bleeding for these (297).  Subcutaneous tunnels do collapse smoothly with 
external compression and hemostasis after removal and do not offer routes for air 
embolisms. 
Retained cuffs do not seem to represent a problem. Surgical removal has been 
routinely offered for the affected patients but all patients deferred. We have not 
encountered subsequent local infections caused by the retained hardware. As we stated in 
our review paper:  
“It appears these structures can be left in place, a scenario analogous to the clotted synthetic 
hemodialysis grafts (297). Alternatively, the retained cuffs can be removed later on, both for 
cause (e.g., migration) or aesthetic reasons via a direct skin excision above it (297). One unusual 
complication for retained cuffs is the potential misinterpretation as a mass on mammogram 
(299). Similar to our results, the published literature appears to quote a rate ≤8% of cuff retention 
(0-10 %) (126, 297). Additionally, cuff retention may be dependent on the catheter material, 
much less with polyurethane-based materials (297). In our inpatient series, we also have 
documented a 0% cuff retention rate (114), but many of those catheters were removed in 
clinically ill hospitalized patients for suspected or proven infections, had breakdown around the 
exit site, etc., thus making cuff retention less likely to occur.”(172)  
A separate issue is the embedded catheter proximal to the entry point in the internal 
jugular vein (300). As we summarized in our review paper:  
“If catheter adherence to central veins or right atrium (301) is suspected, the bedside procedure 
should be aborted and care should be escalated with fluoroscopic guidance and surgical or 
interventional radiology consultation. Accordingly, it is a key for the operators to recognize the 
difficult to remove or (“stuck” or “embedded”) catheter. A very large single-center database 
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spanning nearly a decade suggested this complication in about 1% of long-term dialysis 
catheters (302).  Risk factors for catheter retention include cumulative indwelling time, female 
gender, small vessel caliber, past episodes of infection creating a prothrombotic state and 
repeated catheterizations in the same vessel (303). This situation also appears to occur more 
commonly with catheters implanted into the left internal jugular vein; likely due to the presence 
of more potential friction points associated with the longer catheters, as well as in those with 
ipsilateral intracardiac device wires or stents (304) […] Accordingly, retained catheters fixated 
to the surrounding structures beyond the Dacron cuff may represent a distinct challenge and 
require endoluminal dilatation (305, 306), transcatheter extractor device (307) or laser sheath 
liberation (308), depending on institutional experience and are otherwise well summarized in 
recent reviews (170, 300).”(172) 
 
5.4 Emerging concepts and future directions 
5.4.1 Optimized start for renal replacement therapy  
Multiple studies argue against a preventive or “early” start of renal dialysis (309-
311). In fact, in one of the studies, elderly subjects with early dialysis initiation were 
associated with greater all–cause mortality, cardiovascular mortality and all-cause 
hospitalizations (311). Rather, as stated by the National Kidney Foundation (NKF)-
KDOQI Hemodialysis Adequacy Work Group, initiation maintenance dialysis therapy 
should be based on the presence of symptomatic uremia, protein energy wasting, 
metabolic abnormalities, or volume overload “rather than a specific level of kidney 
function” (312). 
5.4.2 Convective clearance. 
Current studies supporting the value of on-line hemodiafiltration represent almost 
all post-hoc analyses (313, 314), but one study (315), with variation of cut-offs 
representing “sufficient” or “ideal” convective clearance (i.e., the hemofiltration 
component of RRT): >22 L (313), >17.4 L (314) or >18 L (315) per session. A recent 
meta-analysis of 35 trials and more than 4000 patients suggested a lower cardiovascular 
(RR 0.75, 95% CI: 0.58-0.97), albeit not all-cause mortality (RR 0.87, 95% CI: 0.70-1.07) 
with HDF (316). Perhaps not unrelated, intra-dialytic hypotension was also reduced with 
HDF (RR 0.72, 95% CI: 0.66-0.80). None of these studies have been adjusted for the 
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body surface or calculated water space, when calculating the presumed survival effect of 
an achieved HF rate. Further, cost-effectiveness studies suggested quality-adjusted life 
year a cost of HDF vs. HD approximately €287,679 (or approximately 300,000 USD in 
June 2016), above the usually acceptable societal threshold (317). When HD and HDF 
were compared at different treatment times in a small, single-center trial (2x2 factorial 
design, HD vs HDF, 4-hour vs 8-hour treatment times), treatment times, but not modality 
conferred greater hemodynamic stability (9). 
5.4.3 Frequency is not replacing effective time in renal replacement therapy 
Concerns exist with regard to the “stand-alone” frequent dialysis, that is more 
frequent dialysis (>three times a week) without meaningfully extending the weekly time 
spent on renal replacement (318). Commitment of time to travel, logistics of more 
frequent patients’ check-in and check-out procedures, increased utilization of medical 
supplies and increased access complications are additional concerns (319-321). In the 
pivotal Frequent Hemodialysis Network daily trial a statistically significant increase of 
“first access events” (repair, loss, and access-related hospitalizations) was observed 
among frequent dialysis enrollees, compared with a conventional HD group (HR 1.76, 
95% CI: 1.11-2.79; p=0.02). To date, no prospective, randomized controlled trials of 
sufficient power are in existence to report on hard clinical outcomes. On the other hand, 
home dialysis remains a good choice to optimize weekly time on dialysis. Newer and 
simpler technologies (e.g., NxStage Home System, NxStage Medical Inc., Lawrence, 
MA, USA) have simplified the logistics of home dialysis and reduced the time-
commitment for preparations. While most of the existing studies are likely to be 
contaminated by residual confounders, they all suggest survival advantage with more 
frequent standard 3-4-hour sessions (322, 323) or more prolonged (e.g., nocturnal) 
sessions of RRT. 
5.4.4 Gradual escalation of treatment time  
According to current DOPPS data, roughly one-quarter of patients in China 
receive maintenance dialysis only twice a week (26% vs 5%, for the rest of the DOPPS 
regions) (324). Well-preserved RRF may enable such approach in subjects with well-
preserved functional status and less comorbidity. On the other hand, less frequent and 
incrementally increased hemodialysis may preserve RRF longer (325). In a recent, single-
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center Chinese study, independent predictors of RRF loss were thrice-weekly dialyses, 
larger urea reduction ratios and the presence of intradialytic hypotension (326).  
5.4.5 Ensuring the lack of constipation and accelerating gastrointestinal transit time. 
Uremic toxins are generated disproportionally in various body compartments. 
While some tissues (muscles) are more active in that regard than others (fat tissue), the 
largest generating compartment is in fact the interface of human-bacteria in the GI tract. 
In this regard, it would be perhaps most appropriate to view PD as a “compartment 
dialysis” (272), a modality delivering disproportionately large clearance to the gut and 
liver, the very compartments generating most uremic toxins.  Conceptually, this may be 
the largest contributor to the anti-uremic effect of PD, to explain the somewhat 
disconnected effectivity from removals of uremia markers, such as creatinine and blood 
urea nitrogen (BUN). While oral binders of uremic toxins failed to impact renal survival, 
the much simpler clinical question of frequent/loose bowel movements are in fact not 
studied in ESRD, including in anuric ESRD patients. Therefore, the scenario is somewhat 
analogous to end-stage liver disease: to reduce the generation and absorption of uremic 
toxins by inducing a mild state of diarrhea by laxatives. In a small, single-center trial 
(N=20), dietary fiber supplements lowered the level of non-dialyzable colon-derived 
uremic toxin (indoxyl sulfate and p-cresol sulfate) concentrations, presumably by binding 
in the GI tract (327). Similarly, pre- and probiotic supplements may also have the potential 
to lower effective uremic toxin generation and absorption (328). 
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6. Conclusions 
In a single-center trial of eighty-one subjects, we found that fluid overload was 
common (46.9% had VRWG ≥10%) and an important prognostic factor for survival in 
critically ill AKI patients treated with CRRT. Increasing VRWG had a graded adverse 
impact on 30-day survival, with mortality increasing by two and half times in those with 
VRWG ≥10% (OR 2.62, 95% CI: 1.07-6.44; p=0.046) and almost four times with VRWG 
≥20% (OR 3.98, 95% CI: 1.01-15.75; p=0.067) in univariate analysis. Oliguria was also 
a strong predictor of death, with OR for mortality 3.22 (95% CI: 1.23-8.45; p=0.02). Both 
oliguria (OR 3.04, p=0.032) and VRWG ≥10% (OR 2.71, p=0.040) maintained their 
statistically significant association with mortality in multivariate models that included 
sepsis and/or Apache II scoring. Therefore, among the first in adult medicine, we 
established fluid overload before CRRT to be an important prognostic factor for survival 
in critically ill patients with AKI. Further studies are needed to elicit mechanisms and 
develop effective preventive and therapeutic interventions for this very vulnerable group 
of patients. 
We found that treatment time during conventional in-center HD had a significant 
cross-sectional association with serum albumin but not with CRP. In our study of >600 
participants, treatment time longer than four hours was associated with a decreased risk 
of having low (< 40 gm/L) albumin levels with OR of 0.397 (95% CI: 0.235-0.672; 
p<0.001). For elevated CRP, significant correlates were congestive heart failure (OR 
1.634, 95% CI: 1.154-2.312; p=0.006) and acute infection (OR 1.799, 95% CI: 1.059-
3.056; p=0.03).  However, we have not observed an association between UFR and either 
CRP or albumin. To our knowledge, this constituted the first report demonstrating an 
association between treatment time and albumin levels in hemodialysis patients. A large 
number of our patients, both from the European and North American cohorts achieved 
serum albumin and CRP targets, albeit with relatively long treatment times (237.3 ±23.8 
minutes; approximately 16 minutes longer than the US average at that time). This study 
underlines and confirms the critical importance of time in good uremic control.  
We have documented an excellent efficacy (100% success rate) and good safety 
profile during bedside removals of TDC from a combined cohort of two studies and 192 
subjects. About one-third of the TDC removals took place urgently due to bacteremia, 
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and elevated troponin-I had statistically significant associations with catheter-induced 
bacteremia in inpatients (p<0.05). Most (>50%) of the outpatient removals took place due 
to access maturation or cessation of indication for renal dialysis (p<0.0001). During 
outpatient removals, we observed subcutaneous retainer cuff separation in 6.5% of cases, 
all in males. There was a significant association between cuff retention and outpatient 
removal (p=0.007) but not with the operators’ level of training, or the site of removal. 
However, we have not observed catheter body tear or frank complications (major vascular 
damage or air embolism). To our knowledge, these results constituted the first reports 
demonstrating the feasibility and excellent success rate for bedside removal of tunneled-
cuffed permanent hemodialysis catheters by nephrologists. Our results underscore the 
potential for this procedure to enrich clinical nephrology training and contribute to the 
clinical competency of practicing nephrologists. 
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7. Summary 
Medicine is an ever-changing science. Not only our knowledge is changing but also the 
characteristics of the underlying populations. New methods and technology offer not only 
new avenues to address illnesses but new sources of morbidity and mortality as well. 
Volume overload is an emerging marker for the severity of illnesses in critically ill 
patients and a persisting problem in chronic dialysis patients. In critically ill patients with 
acute renal impairment, volume overload may partially mask the elevation of serum 
creatinine and appears to be contributing to adverse outcomes independently. 
Accordingly, volume-related weight gain should be viewed as a prognostic marker on its 
own during the daily evaluation of these patients and conventional indication of renal 
replacement therapy (RRT) may not apply in critically ill patients. In dialysis patients, 
clinical focus is shifting away from a purely biochemical and blood pressure-centered 
viewpoint to a much more patient-centered one, emphasizing effective volume control, 
reducing excess fluid gains and promoting hemodialytic stability during RRT. Time on 
renal replacement therapy is of paramount importance to deliver effective RRT and 
should not be compromised on the patients’ and providers’ convenience. Reduced 
treatment time of less than 4 hours three time a week is associated with likelihood of low 
albumin. Despite recommendations formed by professional societies, hemodialysis 
catheter use is still highly prevalent in end-stage renal disease patients and an ongoing 
source of morbidity and mortality. Every effort should be made to minimize the use and 
duration of indwelling artificial vascular access devices, including timely removal during 
catheter sepsis or after access maturation.  Bedside removal of tunneled-cuffed 
hemodialysis catheters is a safe procedure with minimal complication rate, including 
during graduate medical education by nephrology trainees. New technologies and 
approaches need to be fostered to optimize the delivery of renal replacement therapy and 
to address emerging challenges. 
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8. Összefoglalás 
Az orvostudomány folyamatosan változik. Nem csupán ismereteink bővülnek, hanem a 
vizsgált emberi populációk sajátosságai is változnak. Új módszerek és technológiák 
mindamellett, hogy a gyógyításnak újabb perspektíváit nyitják meg, komplikációk és 
halálozások újabb forrásait is jelenthetik. A folyadék-túlterhelés mértéke - mely egy 
gyakori probléma a krónikus vesepótló terápiára szoruló betegeknél - egy viszonylag 
újonnan felismert jele lehet az általános állapot súlyosságának az intenzív osztályos 
kezelés során. Ezen betegeknél az akut vesekárosodás mellett, a folyadékterhelés mértéke 
részben elfedheti a szérum kreatinin emelkedését, és önmagában is hozzájárulhat a 
szövődmények kialakulásához. Ennek megfelelően a folyadékmennyiséggel összefüggő 
súlynövekedésnek kiemelt prognosztikai fontosságot kell tulajdonítani e betegek napi 
kiértékelése során, ahol a vesepótló terápia (VPT) hagyományos indikációi sem 
feltétlenül alkalmazhatóak. A krónikusan művese kezelésben részesülő betegeknél a 
tisztán biokémiai és vérnyomás-értékre koncentráló megközelítés egyre inkább átadja a 
helyét egy sokkal beteg centrikusabb megközelítésnek, amely a hatékony 
folyadékmennyiség-kontrollt hangsúlyozza, minimalizálva a felesleges folyadékbevitelt 
a kezelések között és hangsúlyozza a hemodinamikai stabilitás fontosságát a kezelések 
alatt. A VPT időtartama kritikus fontossággal bír a kezelés hatékonyságának 
szempontjából, így nem megengedhető, hogy csupán kényelmi szempontok alapján ezt 
csökkentsük.  A heti háromszor kezelt művese betegek esetében, a négy óránál rövidebb 
ideig tartó kezelések az albumin szint csökkenésével járnak. A szakmai testületek által 
javasolt gyakorlat ellenére a hemodialízis katéter használata változatlanul rendkívül 
gyakori a dialízissel kezelt betegeknél, jóllehet a komplikációk és halálozás esélyét 
megnöveli. Mindent meg kell tenni hemodialízis kanülök használatának a 
minimalizására, illetve fertőzés vagy fisztula beérés esetén amilyen hamar csak lehet, 
eltávolításukra.  Az alagutas hemodialízis katéterek betegágy melletti eltávolítása 
minimális komplikációval terhelt orvosi beavatkozás, amely biztonságosan  elvégezhető 
nefrológus szakorvos jelöltek által is a szakképzés során. Új technológiák és módszerek 
sikeres beépítése szükséges, hogy optimalizáljuk a meglévő VPT hatékonyságát, és 
sikerrel nézzünk szembe a reánk váró új kihívásokkal. 
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